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SUMMARY 
This report describes the results of a collaborative study of an HPLC method for the coccidiostat 
maduramicin in four broiler feeds, one turkey feed and one premixture. The collaborative study 
forms part of the EU-project "Development and Validation of HPLC-methods for the official control 
of Coccidiostats and Antibiotics used as Feed Additives (CANFAS-SMT4-CT98-2216). 
The principle of the method is as follows: The sample is extracted with methanol. The content of 
maduramicin is determined by reversed-phase high performance liquid chromatography (HPLC) 
with post-column derivatisation with vanillin and VIS-detection at 520 nm. 
The samples which were tested in the collaborative study were 3 broiler feeds with declared 
maduramicin contents of 2,5, 4,5 and 9 mg/kg, 1 turkey feed with 5 mgAg, 1 blank broiler feed 
and 1 premixture with declared content of 450 mgAg maduramicin. The feed samples were sent 
to the participants as blind duplicates, the premixture as a single sample. The participants were 
asked to do a single determination per sample for the feed samples and to analyse the premixture 
in duplicate. 
Results were reported by 10 laboratories. Statistical evaluation was performed according to ISO 
5725. 
The results of the collaborative study were evaluated in a meeting attended by the participants. 
The panel has accepted the results of the statistical evaluation, as described in Table 7 (including 
the results of lab 26). It can be concluded that the repeatability and reproducibility of the method 
is acceptable, both for feedingstuffs and premixtures. The results obtained for the blind blank 
feeds and for the recovery are also acceptable. The panel agreed that the method can be 
recommended for adoption as an official method. 
Three laboratories used dimethylaminobenzaldehyde (DMAB) for post column derivatisation. The 
results do not differ significantly from the results with vanillin. 
1 INTRODUCTION 
Within the framework of the EU-project "Development and Validation of HPLC-methods for the 
official control of Coccidiostats and Antibiotics used as Feed Additives (CANFAS-SMT4-CT98-
2216), a method was developed for maduramicin. Maduramicin is a coccidiostat which is 
registered for broiler and turkey feeds at a content of 5 mg/kg. 
The method for feeds and premixtures was developed and validated by the Bundesamt und 
Forschungszentrum für Landwirtschaft (BFL), Vienna, Austria (see Final report on method 
development and validation for maduramicin, B. Stoisser, 26-05-1999). Subsequently, the method 
for feeds and premixtures was subjected to between-lab validation by the Universität Hamburg, 
Institut für Angewandte Botanik, Germany (see report H.-A. Putzka, 24-01-2000) and the National 
Veterinary Institute (NVI), Uppsala, Sweden, (see report A. Stepinska, May 2000) with satisfactory 
results (see Second Annual Report CANFAS, J. de Jong, 12-08-2000). 
Prior to the collaborative study, a kick-off meeting was organised (Brussels, 13-14/6/2000) and 
participating laboratories were given the opportunity to familiarise themselves with the method, 
using feed samples with stated contents of maduramicin. Also prior to the production of the 
materials for the collaborative study, separate batches of the materials were produced for 
stability testing, indicating that maduramicin is unstable in feeds and premixtures at room 
temperature and at 37 °C. At 4 °C about 10 % breakdown is observed after 4 months. For this 
reason it was decided to store and ship the samples frozen and to ask the participants to analyse 
the samples in a short period of time after receipt. 
The samples which were prepared for the collaborative study were 3 broiler feeds with declared 
maduramicin contents of 2,5, 4,5 and 9 mgAg, 1 turkey feed with a content of 5 mg/kg, 1 blank 
feed and 1 premixture with declared content of 450 mg/kg maduramicin. The feeds with 2,5 and 
9 mg maduramicin per kg have been included in order to assure that the method is applicable for 
contents 2 times lower and 2 times higher than the permitted content. 
The feed samples were sent to the participants as blind duplicates, the premixture as a single 
sample. The participants were asked to do a single determination per sample for the feed 
samples and to analyse the premixture in duplicate. Before these samples were shipped, the 
between-sample homogeneity was checked with satisfactory results (see par. 3.1.2). 
Apart from the samples, a letter with instructions, reporting forms, etc. was sent to the 
participants (see Appendix 1). 
This report describes the results of the collaborative study. 
2 PARTICIPANTS 
The following laboratories/persons participated in the collaborative study. 
- Bundesambt und Forschungszentrum für Landwirtschaft (BFL), Wien, Austria; B. Stoisser, M. 
Wieshaider 
- Hoffmann-La Roche Ltd., Basel, Switzerland; P. Hofmann, A. Zuber 
- IEEB, Bordeaux, France; J.P. Antalick, T. Gron. 
- INETI/DTIA, Lisbon, Portugal; I. Felgueiras, C. Saldanha. 
- Laboratory of the Government Chemist, Teddington, United Kingdom; G. Merson, J. Cowles, 
K. Needham. ± 
- LUFA - Augustenberg, Karlsruhe, Germany; A. Thalmann, K. Wagner 
- LUFA-ITL Kiel, Kiel, Germany; F.H. Johannsen, Kollwitz. 
- Masterlab, Putten, The Netherlands; K. van Schalm, A. Schaaf. 
- National Veterinary Institute, Uppsala, Sweden; E. Nordkvist, A. Stepinska 
- Rijksontledingslaboratorium, Tervuren, Belgium; K. Haustraete, A. Fontaine, M. Bral, R. van 
San 
- RIKILT, Wageningen, The Netherlands; H.J. van der Kamp, H.C.H. Kleijnen 
- Universität Hamburg, Institut für Angewandte Botanik, Hamburg, Germany; H. Putzka, D. 
Böhm. 
3 MATERIALS 
3.1 Samples for collaborative study 
3.1.1 Sample composition 
Specifications of the samples, which were produced for the collaborative study, are given in 
Table 1. 
Table 1 : Specifications of the samples 
Type of feed / 
premixture 
Broiler feed 1, 4 % fat 
Broiler feed 1, 4 % fat 
Broiler feed II, 8 % fat 
Turkey feed 
Premixture for broiler 
feed 
Declared 
content 
2,5 
9 
4,5 
5 
450 
Units 
mgAg 
mgAg 
mgAg 
mgAg 
mgAg 
Subcontractor 
Hoffmann-La Roche 
Hoffmann-La Roche 
Hoffmann-La Roche 
Hoffmann-La Roche 
Hoffmann-La Roche 
Date of 
production 
29/09/2000 
29/09/2000 
29/09/2000 
29/09/2000 
25/08/2000 
The broiler feeds contained wheat, broken rice, soya extruded, corn gluten feed and pig fat in 
the usual industrial quantities. The turkey feed contained wheat, corn, soya expellers, rape, 
peas, potato protein and pig fat in the usual industrial quantities. The complete composition of 
the feeds is stored in the files of the co-ordinator (confidential). The premixture was based on 
wheat middlings as carrier material and contained regular contents of vitamins, minerals and 
trace elements. 
The composition of the turkey feed and the premixture was the same as the composition of the 
products that were produced by Hoffmann-La Roche in August 1999 for stability testing (see 
Report on homogeneity and stability studies of samples for the collaborative studies for 
maduramicin, B. Stoisser, BFL, Vienna, Austria, 31.01.2000). For the broiler feeds, the 
composition had to be adapted because, due to the BSE-measures, some of the ingredients 
were no longer available. 
The feed products have been prepared in a quantity of 30 kg each (10 kg went to waste, 20 kg 
were used). 50 subsamples of approx. 250 grams have been taken (manual distribution with a 
shovel). The subsamples were stored in minigrip PE sacks. 
The premixture has been prepared in a quantity of 5 kg. From the premixture 35 subsamples of 
approx. 100 g have been taken (manual distribution with a shovel) and supplied in minigrip PE 
sacks. 
All subsamples have been stored frozen (- 20 °C). 
Next to the above mentioned samples which contained maduramicin, a blind blank feed was sent 
to the participants as well as a blank feed labelled "blank feed for maduramicin recovery check" 
(see Appendix 1). The blind blank feed was the broiler I type feed (see above). This feed was 
analysed at F. Hoffmann-La Roche Ltd prior to the collaborative studies and was found to contain 
no detectable amounts of maduramicin or interfering substances. The blank feed for 
maduramicin recovery check was the same broiler I type feed. 
3.1.2 Sample homogeneity 
The homogeneity of the samples was studied by BFL by random selection of 10 subsamples, 
applying the HPLC-method developed in CANFAS (see Annex 1 of Appendix 1). 
The results of the homogeneity determinations of the individual feeds / premixture are attached 
in Appendix 2. Table 3 gives a summary of these results. 
<L 
Table 3: Results of homogeneity tests for maduramicin in feeds and premixture 
" \ Results 
Product \ . 
Broiler feed 1. 
4 % fat 
Broiler feed 1. 
4 % fat 
Broiler feed II. 
8 % fat 
Turkey feed 
Premixture 
Declared 
content 
(mgAg) 
2,5 
9 
4,5 
5 
450 
Measured 
content 
(mgAg) 
2,69 
9,89 
5,03 
5,12 
487 
Homogeneity results 
Between sample 
CV (%) 
4,4 
4,2 
2,4 
3,1 
4,4 
Within sample CV (%) 
6,2 
7,9 
4,3 
3,7 
4,6 
According to the Project Plan the CVs for homogeneity should not exceed 2 times the CV's for 
repeatability (CVhom < 2 CVr). Based on previous results of within-lab validation (see Second 
Annual Report CANFAS, J. de Jong, 12-08-2000) the maximum limit for CVhom was set to 15 % 
for the feed containing 2,5 mgAg and 12 % for the other feeds and the premixture. 
All between- and within-sample CVs fulfil these requirements. Thus, it is concluded that the 
samples are sufficiently homogeneous. 
3.1.3 Sample logistics 
The feed samples were sent as blind duplicates. The codes are given in Appendix 3. The 
premixture was sent as a single sample and was labelled as such. The samples were sent to the 
participants from Hoffmann-La Roche by courier service on 14 November 2000. The samples 
were shipped frozen on dry ice. 
3.2 Reference standard 
The reference standard was supplied by dr. P. Hofmann, Hoffmann-La Roche, Basel, Switzerland. 
The certificate of analysis of the reference standard (Lot No. AC 9745-1C) is described in 
Appendix 4. The purity of this standard, expressed as the ammonium-salt, is 93,3 %. This 
information is described on the label of the reference standard vials and should be used in the 
calculations (see method). In addition to the information already given, the participants were 
instructed by E-mail to set the purity of the reference standard to 93,3 %. Moreover, the 
participants were also instructed by E-mail that, contrary to the information on the certificate of 
analysis, the reference standard should be used as such and should not be dried. 
4 METHODS 
4.1 Method of analysis 
The method of analysis is included as annex 1 to Appendix 1. The participants were instructed 
that this method has to be used without any modifications. 
4.1.1. HPLC-conditions 
Various types of HPLC-columns were used (the column which is recommended in the method is 
a Hypersil BDS C18, 250x4,6mm, 5 urn). 
The mobile phase described in the method is phosphate buffer 10 mM, pH=4,0 : methanol = 
100:900 (v/v). One laboratory used a different mobile phase. ^ 
The HPLC conditions (Column and mobile phase) used by the participants are shown in Table 4. 
Table 4: HPLC-conditions 
Partner 
17 
22 
23 
26 
27 
29 
30 
31 
35 
36 
Column 
As described in the method 
As described in the method 
Not reported 
Sperisorb ODS-2 
As described in the method 
Spherisorb ODS-3, CI8, 4,6x250 
mm, 5 urn 
Kromasil C18 150 x 4,6 mm 5um 
As described in the method 
Lichrospher 100 RP18 (5 urn) 
Hypersil ODS, 5 urn, 250x4 mm 
Mobile phase 
As described in the method 
As described in the method 
Not reported 
As described in the method 
As described in the method 
As described in the method 
As described in the method 
As described in the method 
As described in the method 
100 ml phosphate buffer pH 4, 80 ml 
tetrahydrofurane, to 1000 ml with methanol 
4.2 Method for statistical evaluation 
Statistical evaluation was performed according to ISO 5725 Part 2: Basic method for the 
determination of repeatability and reproducibility of a standard measurement method (First 
edition, 1994-12-15). 
The scrutinity of results for consistency and outliers was checked by 
a) Graphical consistency techniques: Mandel's h plot for between-laboratory variability, Mandel's 
k plot for within-laboratory variability 
b) Numerical outlier techniques: Cochran's test of the within-laboratory variability, Grubbs' test 
(single and double) for between-laboratory variability 
10 
Whenever necessary and appropriate, laboratories which showed consistently high within-cell 
variation and/or extreme cell means across many levels and/or Cochran or Grubbs' outliers were 
contacted to try to ascertain the cause of the discrepant behaviour. 
The Horwitz equation and the HORRAT ratios form the basis for the evaluation of the 
reproducibility of the method. The HORRAT ratios are given in Table 5. The HORRAT ratios should 
be lower than 2 (see W. Horwitz and R. Albert, J.A.O.A.C. 74 (1991) 718-744). 
H 
RESULTS 
For each participant the reported results for the samples, the completed questionnaire and 
representative chromatograms are annexed in Appendix 5. 
5.1 Statistical evaluation 
The results reported by the participants are given in Table 7. 
The results of lab 29 for the 450 mg/kg sample were discarded for the following reason: due to 
the fact that the extract of the premixture was not diluted, the value for the peak area was much 
higher than the area value for the highest standard (see Remarks, Table 11). 
Statistical analysis of the results (excl. lab 29, 450 mg/kg sample) showed that lab 30 is a 
Cochran outlier for the 5 mg/kg sample. The resulting values for the statistical parameters (mean, 
relative standard deviations for repeatability and reproducibility) are given in Table 7. According to 
the Project Plan, the rsdr-values should be < 10 %. For all samples this criterion is met and 
consequently it can be concluded that the repeatability is satisfactory. 
The Horwitz equation and the HORRAT ratios form the basis for the evaluation of the 
reproducibility (see W. Horwitz and R. Albert, J.A.O.A.C. 74 (1991) 718-744). The HORRAT ratios 
are given in Table 5. The HORRAT ratios should be lower than 2. For all five samples this criterion 
is met and established rsdR-values are in line with values predicted by the Horwitz equation. 
Consequently it can be concluded that the reproducibility of the method is satisfactory. 
Table 5: Horrat ratios of the Maduramicin collaborative study 
Mean after elimination Predicted 
of outliers1 (mg/kg) rsdR 
2,616 13,844 
4,438 12,785 
5,052 12,538 
9,374 11,424 
464,3 6,349 
Established 
rsdR 
15,270 
25,350 
16,120 
16,820 
11,450 
Horrat2 
1,10 
1,98 
1,29 
1,47 
1,80 
Conclusion 
Reproducibility OK 
Reproducibility OK 
Reproducibility OK 
Reproducibility OK 
Reproducibility OK 
1
 = lab 29/sample 450ppm; lab 30/sample 5 ppm 
2
 = Horrat is the ratio between the established rsdR and the predicted rsdR 
Lab 26 reported a recovery (80 %) much lower than the mean recoveries of the other 
laboratories, which are all higher than 90 % (see par. 5.3). The latter is in line with the results 
obtained in the method development and between-lab validation phases of the CANFAS project 
where recoveries were consistently higher than 90 % (see Second Annual Report CANFAS, J. de 
Jong, 12-08-2000). The Mandel h plot (see Figure 1) shows low results for lab 26 across all 
levels. This could be caused by a systematic low recovery for the method in this lab. Together 
with the results, lab 26 had already indicated that they had a number of problems with the 
12 
chromatography, mainly with regards to the sensitivity of the method (see par. 5.4). Lab 26 was 
contacted to try to ascertain the cause of the discrepant behaviour. The lab suggested that the 
low results could be caused by degradation of the samples because "the final analysis was 
undertaken at the extreme limit of the time permitted. We may have experienced a degree of 
sample degradation even though the samples were kept frozen throughout the time period 
between receipt and final analysis". The suggested sample degradation is not very likely because 
a number of other labs performed the analyses later than lab 26. 
During the evaluation meeting it has been discussed with relation to the above-mentioned reasons 
whether the results of lab 26 should be discarded or not. The results of the discussions are 
described in Chapter 6 of this report. 
When the results of lab 26 are discarded, statistical analysis of the results shows that lab 30 is 
still a Cochran outlier for the 5 mgAg sample. The resulting values for the relative standard 
deviations for repeatability are not very different from the values including lab 26 (see Table 8). 
The resulting values for the relative standard deviations for reproducibility and the HORRAT ratios 
are slightly improved (see Table 6). 
Table 6: Horrat ratios of the Maduramicin collaborative study after discarding lab 26 
[Mean after elimination Predicted rsdR 
of outliers1 (mgAg) 
2,679 13,794 
4,543 12,740 
5,184 12,490 
9,654 11,374 
|472,0 6,334 
Established rsdR 
13,570 
25,070 
14,690 
14,140 
9,195 
Horrat2 
0,98 
1,97 
1,18 
1,24 
1,45 
Conclusion 1 
Reproducibility OK 
Reproducibility OK 
Reproducibility OK 
Reproducibility OK 
Reproducibility OK 
1
 = lab 29/sample 450ppm; lab 30/sample 5 ppm 
2
 = Horrat is the ratio between the established rsdR and the predicted rsdR 
The corresponding Mandel h and k plots are shown in Figure 2. 
13 
Table 7: Maduramicin in one turkey feed, four broiler feeds and one premixture for broiler 
feed 
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Table 8: Maduramicin in one turkey feed, four broiler feeds and one premixture for broiler 
feed after elimination of lab 26 
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Figure 1: Mandel h and k plots after elimination of lab 29 (450 mgAg) and lab 30 (5 mgAg) 
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Figure 2: Mandel h and k plots after elimination of lab 29 (sample 450 mg/kg), 
lab 30 (sample 5 mgAg) and all results of lab 26 
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5.2 Blank samples 
Table 9: Reported results of the participants for the blank samples 
Partner 
17 
22 
23 
26 
27 
29 
30 
31 
35 
36 
Blank sample 1 
-
<1 
<0,39 
0,8 
Not detectable 
0 
<1 
0 
<2 
0 
Blank sample 2 
-
<1 
<0,39 
0,7 
Not detectable 
0 
<1 ^ 
0 
<2 
0 
One laboratory (nr 26) detected a signal in the blank samples, corresponding to 0,8 and 0,7 
mgAg- This signal was below their limit of quantification, which was estimated at 1 mgAg-
5.3 Recoveries 
Table 10: Recoveries 
Partner 
17 
22 
23 
26 
27 
29 
30 
31 
35 
36 
Recovery 1 in % 
99 
99 
Not reported 
80 
103 
100 
103 
99 
111 
97 
Recovery 2 in % 
100 
103 
110 
101 
106 
95 
Recovery average in % 
100 
101 
80 
103 
105 
103 
100 (day 1) 
108 (day 2) mean: 104 
96 
99 (feeds) 
99 (premixes) 
Except for lab 26, all recoveries were higher than 90% (see also paragraph 5.1). The result of lab 
26 (80% recovery) is a straggler according to the Grubbs' test. 
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5.4 Remarks 
Table 11 : Remarks made by the partners 
Partner 
17 
22 
23 
26 
27 
29 
Remarks 
No remarks 
The lower limit 0,2 ug/ml was the lowest standard concentration achievable due to the 
ripple in the base-line. 
Not reported 
- The extraction and clean up was straightforward and easy to follow. 
- We had a great number of problems with the chromatography. 
- The documentation does not mention the need to eliminate all stainless steel 
fittings between the mixing chamber and detection 
- Even with the recommended length of tubing between the reaction coil and the 
detector we found it impossible to eliminate the baseline noise. 
- As a result of the baseline noise we found it very difficult to integrate the lowest 
standard consistently even with a 100 ul injection loop 
- After several runs we experienced an increase in back pressure generated by the 
mixing chamber 
- Due to the above and pressure of time we are able to submit only 1 result for the 
premix. 
There were no problems. On the four days, when analyses have been done, the 
linearity of the calibration graphs area vs. Concentration (from 0,2 ug/ml to 2,0 ug/ml) 
can be described as follows: 
r= 0,999987; 0,999852; 0,999947; 0,999724 
Two remarks to the method description: 
- In the chapter "Apparatus"(4.3.3) and in the chapter "Parameters" (5.3.1) you 
should write 5 urn for the particle size of reversed phase material in the analytical 
column instead of 5 u. 
In the chapter "Parameters, mobile phase" (5.3.1) the mixing proportion of the mixture 
of phosphate buffer solution with methanol (100 + 900 [V+V]) does not correspond 
exactly to that one described in the chapter "Reagents" (3.7) because of the 
phenomenon of volume contraction. 1 would like to write "mixture (Vmi) of phosphate-
buffer solution (Vp) with methanol 100/1000 (Vp/Vmi)". 
We made some little modifications on the method such as: 
- The decanted supernant was placed in the refrigerator overnight, in feedingstuffs 
and in premixtures (5.2.1, 5.2.2) and not in the freezer for 2-3 hours. 
- There was no dilution for premix, but maybe it would be more correct to do one 
because the value for the peak area was much higher than the area value for the 
highest standard (187 ug/ml). 
- The reaction temperature was settled at 98-100 °C. 
- The injection was of 200 ul and not 50 ul because of the detector sensitivity. 
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Partner 
30 
31 
35 
36 
Remarks 
The method is not sensitive enough. The risk of interference of other ionophores is 
important. 
Temperature of reaction was 98 °C instead of 95 °C. This method has to be 
considered as semi quantitative because of the low signal to noise ratio. The results 
were strongly influenced by the integration with the Turbochrom program. It was not 
possible to fix a clear baseline. • 
No remarks 
We used our in-house method. (Note form the co-ordinator: this method only differs 
with regards to the chromatographic conditions and consequently it can be regarded 
as equivalent. No recovery experiments have been performed; recovery^experiments 
are part of our in-house validation. 
5.5 Special requests 
The following partner performed another method (Cyanamid method, pre-column derivatisation 
with dansylhydrazine) 
- Rijksontledingslaboratorium, Tervuren, Belgium; K. Haustraete, A. Fontaine. 
The following partners performed the post-column derivatisation reaction with DMAB 
(dimethylaminobenzaldehyde) instead of with vanillin: 
- LUFA - Augustenberg, Karlsruhe, Germany; A. Thalmann, K. Wagner, 
- Hoffmann-La Roche Ltd., Basel, Switzerland; P. Hofmann, A. Zuber 
- Universität Hamburg, Institut für Angewandte Botanik, Hamburg, Germany; H. Putzka, D. 
Böhm. 
5.5.1 HPLC conditions 
Table 12: HPLC conditions 
Partner 
Rijksontledingslaboratorium 
Tervuren, Belgium 
LUFA - Augustenberg, 
Karlsruhe, Germany 
Hoffmann-La Roche Ltd., 
Basel, Switzerland 
Universität Hamburg, Institut 
für Angewandte Botanik, 
Hamburg, Germany 
Column 
Hypersil ODS, 25 cm x 4,9 
mm 
Hypersil ODS, 5 um 
250x4,6 mm 
Hypersil ODS, 5 um, 250 x 
4 mm 
As described in the method 
Mobile phase 
TBAS solution : acetonitril = 
20:80 (v/v) 
As described in the method 
100 ml Phosphate buffer pH4, 
80 ml tetrahydrofurane, to 1000 
ml with methanol 
As described in the method 
5.5.2 Recoveries 
Table 13: Recoveries 
Partner 
Rijksontledingslaboratorium 
Tervuren, Belgium 
LUFA - Augustenberg, 
Karlsruhe, Germany 
Hoffmann-La Roche Ltd., 
Basel, Switzerland 
Recovery 1 in % 
95 
104 
Recovery 2 in % 
100 
Recovery average in % 
95 
102 
99,4 (feed) 
99,3 (premixes) 
5.5.3 Remarks 
Table 14: Remarks made by the partners 
Partner 
Rijksontledingslaboratorium 
Tervuren, Belgium 
LUFA - Augustenberg, 
Karlsruhe, Germany 
Hoffmann-La Roche Ltd., 
Basel, Switzerland 
Universität Hamburg, Institut 
für Angewandte Botanik, 
Hamburg, Germany 
Remarks 
The Cyanamid method was followed because with the proposed 
CANFAS method problems with sensitivity and problems with the 
post-column derivatisation (air bubbles and non stabile system) 
occurred. 
The reason for post-column derivatisation with DMAB instead of 
with vanillin was that the reaction with vanillin was too weak 
No remarks 
As to post-column derivatization with "DMAB-reagenf one test 
was made with 3 different standard solutions and 2 sample 
extracts. The conditions were nearly the same as with the 
prescribed vanillin method, i.e. we used the same post column 
reactor coil and the temperature of the water bath was 93°C. 
Reagents 3.13. and 3.14 were mixed (1+1/v+v) and thus 
added by 1 pump, but the flow rate of the post-column reagent 
was only 0,4 ml/min (the same as with the vanillin reagent), the 
flow rate of the mobile phase was 0,4 ml/min as well, injection 
volume was 50 ul, wavelength for detection 600 nm. Result: The 
corresponding signals for the area were about 5% higher than 
those caused by the vanillin reagent (on an average). 
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5.5.4 Results of the samples 
Table 15: Results reported by the partners 
Partner 
Method 
Sample 
content 
(mgAg) 
0 
0 
2,5 
2,5 
4,5 
4,5 
5 
5 
9 
9 
Premixture 
Rijksontledingslaboratorium 
Tervuren, Belgium 
Cyanamid 
<1 
<1 
2,6 
2,9 
4,7 
4,6 
4,9 
5,3 
9,3 
8,6 
276 276 
LUFA - Augustenberg, 
Karlsruhe, Germany 
DMAB 
Hoffmann-La Roche 
Ltd., Basel, Switzerland 
DMAB 
Reported result (mgAg) 
0 
0 
2,4 
2,3 
4,9 
4,6 
4,6 
4,1 
9,1 
8,9 
443 528 
0 ± 
Not analysed 
2,9 
Not analysed 
3,9 
Not analysed 
Not analysed 
Not analysed 
8,7 
Not analysed 
Not analysed 
Representative chromatograms of LUFA-Augustenberg and Hoffmann-La Roche are included in 
Appendix 6. 
The results obtained with DMAB do not differ significantly from the mean values obtained with 
vanillin (see paragraph 5.1). Applying pre-column derivatisation with dansylhydrazine, for feeds 
the same conclusion can be drawn but for the premixture significantly lower values are obtained. 
The reason for this is not clear. 
6 EVALUATION AND CONCLUSIONS 
The results of the collaborative study were evaluated in a meeting in Tervuren (Belgium) on June 
19-20,2001. 
After thorough discussions the panel decided that the results of lab 26 should be taken into 
account in the statistical evaluation. The relatively low results at all levels (see Mandel h plot, Fig. 
1) do not justify removal of the results because only 1 value is below the 5 % indicator line. The 
problems with the sensitivity of the method that were reported by lab 26 are no reason to remove 
the results because some other laboratories experienced the same problem. During the meeting 
the question was raised if the recovery value reported by lab 26 (80 %) is an outlier. This was 
checked later on by Jaap Driessen (RIKILT): lab 26 is a Grubbs' straggler, but not a Grubbs' 
outlier. 
The panel has accepted the results of the statistical evaluation, as described in Table 7 (including 
the results of lab 26). Consequently it can be concluded that the repeatability and reproducibility 
of the method is acceptable. The results obtained for the blind blank feeds and for the recovery 
are also acceptable. The panel agreed that the method can be recommended for adoption as an 
official method. 
The co-ordinator will send an enquiry to the participants about the type of detector that has been 
used, any special arrangements to increase the sensitivity in the VIS region and about the data 
acquisition system applied. 
The following points will be changed in the method: 
- The use of stainless steel tubing in the post-column reactor and detector should be avoided 
- A remark will be added about the suitability of DMAB for post-column derivatisation, stating 
that a full validation with DMAB has not been performed 
The following remarks, related to the method description have been accepted: 
- Lab 27, remarks about particle size and mobile phase composition 
The method description will be modified and the final method, together with the results of the 
collaborative study will be sent to the European Commission (CEMA), CEN and ISO. 
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APPENDIX 1 
Letter with instructions, sent with the samples (with five annexes) 
cc(T)riess8n, De Jong 
to addressee 
«L 
Dear colleague, 
With separate post the samples for the collaborative study for maduramicin will be sent 
to you by dr. Hofmann (Hoffmann-La Roche). We expect the samples will be sent within 
one or two weeks from now. You will receive the following samples : 
• 10 feed samples, with the text "additive: MADURAMICIN" and with a sample code; 
these samples constitute 4 blind duplicates of feed samples containing 
maduramicin (contents in the range between 1 and 15 mgAg) and 1 blind duplicate 
of a blank feed 
• 1 premixture containing maduramicin, content in the range between 200 and 1000 
mgAg. 
As discussed in the kick-off meeting, please store the samples frozen and 
perform the analysis within 2 weeks after receipt 
For the feed samples you are asked to do a single determination per sample, the 
premixture must be analysed in duplicate. 
For recovery purposes, a blank sample with the text "blank broiler feed for maduramicin 
recovery check" will be included. 
The method which has to be used is included as Annex 1 (please note that this method is 
a modified'version of the method which was distributed prior to the kick-off meeting). 
Annex 2 contains the reporting form. This form has already been send to you by E-mail 
as an Excel 5.0 file. We strongly prefer to get the results back in electronic form by E-
mail (please send the results to the following E-mail address: j.j.m.driessen@rikilt.wag-
ur.nl). Of course you can also fill in the form and send it by fax or normal mail. 
The deadline for reporting the results is 22 December 2000. 
DATE 
25 October 2000 
SUBJECT 
collaborative study CANFAS 
maduramicin 71.316.24 
ENCLOSURE!!) 
5 
OUR REFERENCE 
00/0024096 
HANDLED BY 
Dr. J. da Jong 
DIRECT ITELEPHONEI LINE 
+31 317 47 55 81 
EMAIL 
j.dajong«RIKILT.WAG-UR.nl 
RIKILT 
State Institute for Quality 
Control of Agricultural 
Products 
P.O.Box 230 
6700 AB Wageningen 
The Netherlands 
VISITORS' ADDRESS 
Building no. 123 
Bornsesteeg 45 
6708 PD Wagoningen 
TELEPHONE 
+31 317 47 54 00 
FA« 
•31 317 41 77 17 
CHAMBER OF COMMERCE REGISTRATION NO. 
09098104 te Arnhem 
THE INTERNET 
<r.rlkiit.wageningen-ur.nl 
Annex 3 contains instructions for handling (milling, storage) of the samples. 
Annex 4 is a questionnaire. We kindly ask you to give us information about the 
experimental conditions, recoveries, etc.. On this form you can also give your remarks 
about the method. 
Annex 5 contains information about special requests. We hope that, next to the regular 
determinations, you are prepared to volunteer to do extra work with post-column 
derivatisation with DMAB. 
The reference standard of maduramicin which has to be used will be send to you by Mr. 
Hofmann (Hoffmann-La Roche) together with the samples. In the calculations please take 
into account the purity of the reference standard. 
We wish you and your colleagues the best with the collaborative studies. If you have any 
questions, do not hesitate to contact us. 
Kind regards, 
dr. Jacob de Jong ing. J.J.M. Driessen 
CANFAS coordinator coordinator CANFAS 
collaborative studies RIKILT 
Stat* Institut* for Quality Contr 
of Agricultural Products 
OtTl 
25 Octobar 2000 
OUR DEFERENCE 
CC 00/0024096 
Mrs. D. Bennink, European Commission, DG Research, CII/3, Brussels £« 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Annex 1 - Description of the method 
CANFAS/MAD/09102000/B.STOISSER 
DETERMINATION OF MADURAMICIN-AMMONIUM 
1 PURPOSE AND SCOPE 
The method is for the determination of maduramicin in feedingstuffs and premixtures. 
The usual concentration of maduramicin in feedstuffs is 5 mg/kg, in premixtures 500 
mg/kg. The limit of determination is 2 mg/kg. The limit of detection is 0,5 mg/kg. 
2 PRINCIPLE 
The sample is extracted with methanol. The content of maduramicin is determined by 
reversed-phase-high-performance-liquid chromatography (HPLC) with post column 
derivatisation with vanillin using a Vis-detector. 
3 REAGENTS 
3.1 Methanol, HPLC-grade 
3.2 1,5-Dlmethylhexy (amine 
3.3 Sulfuric acid, 95-97%, p.a. 
3.4 Ortho-phosphoric acid, appr. 85%, p.a. 
3.4.1 Diluted o-phosphoric acid: 
Dissolve 10 ml of o-phosphoric acid (3.4) to 100 ml with demineralised water 
3.5 Potassium dihydrogen phosphate, p.a. 
3.6 Phosphate buffer solution 10 mmol/l, pH=4,0: 
Dissolve 1.36 g of potassium dihydrogen phosphate (3.5) in 500 ml of demineralised 
water. Add 3.0 ml of o-phosphoric acid (3.4) and 10 ml of 1,5-dimethyl hexylamine 
(3.2). Adjust the pH to 4.0 with diluted o-phosphoric acid (3.4.1) and fill with 
demineralised water to 1000 ml. 
The solution can be stored some weeks, but if fungus grow, prepare a new one. 
3.7 Mobile phase: 
Dilute 100 ml of phosphate-buffer solution 10 mmol/l, ph=4 (3.6) with methanol (3.1) 
to 1000 ml. 
3.8 Vanillin £ 98% (HPLC) 
3.8.1 Vanillin reagent: 
Dissolve 10 g of vanillin (3.8) in a mixture of 250 ml of methanol (3.1) and 5.0 ml of 
sulfuric acid (3.3). Mix well and sonicate for some min under vacuum at room 
temperature. This solution has to be prepared daily prior to use and has to be cooled 
with ice water during use. 
1/5 
3.9 Maduramicin K+-salt (8.4) 
The purity-grade accounted as NH4+-salt has to be taken into consideration at the 
following operations 
3.9.1 Stock-standard-solution 100 ug/ml: 
Dissolve in a 100 ml volumetric flask to the nearest 0.1 mglO mg of reference 
standard (3.9) with methanol (3.1) to 100 ml. This solution should be stored at 4°C not 
longer than 1 month. 
3.9.2 Standard solution 10 ug/ml: 
Dilute 10.0 ml of the stock-standard-solution (3.9.1) to 100 ml with methanol (3.1) in 
a 100 ml volumetric flask 
Standard solutions should be stored at 4°C not longer than 1 week. ^ 
3.9.3 Standard solution 1 ug/ml 
Dilute 2.0 ml of the stock-standard-solution (3.9.1) to 200.0 ml with methanol (3.1) in 
a 200 ml volumetric flask. 
Standard solution should be prepared freshly 
3.9.4 Calibration solutions 
Into a series of 50 ml graduated flasks transfer 1.0,2.0,3.0,4.0,5.0, 6.0,8.0, and 
10.0 ml of the intermediate standard solution (3.9.2). Make up to the mark with 
methanol and mix. These solutions correspond to 0.2,0.4,0.6,0.8,1.0,1.2,1.6, and 
2.0 ug of maduramicin per ml respectively. 
Calibration solutions should be prepared freshly 
4 APPARATUS 
4.1 Centrifuge 
4.2 Ultrasonic bath 
4.3 HPLC-equfpment 
with pump and column oven 
4.3.1 Autosampler with injection system, 
suitable for injection of 50 ul 
4.3.2 (UV)-Vis-detector (8.1) 
4.3.3 Liquid chromatographic column 
250x4.6 mm,5u,Hypersil BDS C 18 or equivalent 
4.3.4 Reagent pump 
4.3.5 PEEK mixing chamber 
4.3.6 PTFE reaction coil (knitted) (8.3) 
0.5 mm x 10 m (volume «2.0 ml) 
4.3.7 Reactor oven for the PTFE-reaction coil, 
suitable to 100°C (or suitable water bath) 
4.4 Freezer 
4.5 Membrane-filter, PTFE , 0.22pm 
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5 PROCEDURE 
5.1 General 
5.1.1 Blank feed 
For the performance of the recovery test (5.1.2) a blank feed should be analysed to 
check that neither maduramicin nor interfering substances are present. The blank feed 
should be similar in type to that of the sample and maduramicin or interfering 
substances should not be detected. 
5.1.2 Recovery test 
A recovery test should be carried out by analysing the blank feed which has been 
fortified by addition of a quantity of maduramicin, similar to that present in the 
sample. To fortify at a level of 5 mg/kg transfer 500 ul stock-standard solution 
(100 ug/ml (3.9.1)) to the flask. Add 10 g of the blank feed, mix thoroughly and leave 
for 10 min, mixing again several times before proceeding with the extraction step 
(5.2). 
Alternatively, if a blank feed similar in type to that of the sample is not available ( see 
5.1.1 ), a recovery test can be performed by means of the standard addition method. In 
this case, the sample to be analysed is fortified with a quantity of maduramicin similar 
to that already present in the sample. This sample is analysed together with the 
unfortified sample and the recovery can be calculated by subtraction. 
5.2 Extraction 
5.2.1 Feedingstuffs 
Weigh to the nearest 0.01 g 10 g of the £ 1mm ground sample into a 250 ml 
volumetric flask and add 50 ml methanol (3.1) . Close the flask with a suitable 
method, and place in a ultrasonic bath at 50° C for 20 minutes. Shake vigorously, store 
and cool down to room temperature appr. 15 min, decant the clear supernant and place 
in freezer for 2 - 3 hours to settle down fat. Then centrifuge an aliquote for 1-2 min. 
After membrane (4.5) filtration 50 ul of this solution are injected into the HPLC-
apparatus. 
5.2.2 Premixes 
Weigh to the nearest 0.01 g i g of the < 0.5mm ground sample into a 250 ml 
volumetric flask and add 50 ml methanol (3.1) . Close the flask with a suitable 
method, and place in an ultrasonic bath at 50° C for 20 minutes. Cool down to room 
temperature, shake vigorously, store some minutes and dilute an aliquote 1 :10 of the 
clear supernatant with methanol and place in freezer for 2-3 hours to settle down fat. 
Then centrifuge an aliquote for 1-2 min. After membrane (4.5) filtration 50 ul of this 
solution are injected into the HPLC-apparatus. 
5.3 HPLC determination 
5.3.1 Parameters: 
The following conditions are offered for guidance, other conditions may be used 
provided that they give equivalent results. 
Analytical column (4.3.3) 250 x 4.6 mm, 5n, Hypersil BDS C 18 
Mobile phase (3.7) Mixture of phosphate-buffer solution (3.6) with 
methanol (3.1), 100 + 900 (V + V) 
Column oven: 40°C 
Flow rate: 0.4 ml/min 
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Flow rate reagent pump: 0.4 ml/min 
Reactor temperature: 95°C (8.2) 
Detection wavelength: 520 nm 
Injection volume: 50 jil 
Retention time: approx. 25 min 
Run time: 30 -35 min 
Check the stability of the chromatographic system, injecting several times the 
calibration solution (3.9.3) containing 1.0 ug/ml, until constant peak areas and 
retention times are achieved. 
Working with the described conditions there is baseline separation from other 
ionophores like salinomicin, narasin, monensin, semduramicin. 
5.3.2 Calibration graph ^ 
Inject each calibration solution (3.9.4) several times and determine the mean peak 
areas for each concentration. Plot a calibration graph using the mean peak areas of the 
calibration solutions as the ordinate and the corresponding concentrations in ug/ml as 
the abscissae. 
5.3.3 Sample solution 
Inject the sample extract (5.2) at least 2 times using the same volume as taken for the 
calibration solutions and determine the mean peak area of the maduramicin peaks. 
6 CALCULATION OF THE RESULTS 
From the mean area (8.5) of the maduramicin peaks of the sample solution determine 
the concentration of the sample solution in ug/ml by reference to the calibration graph 
(5.3.2) 
The maduramicin content in mg/kg of the sample is given by the following formula: 
mg maduramicin/kg 
C . 50 . F 
M 
C = maduramicin concentration of the sample extract (5.2) in ug/ml 
M = mass of the test portion in g 
F = dilution factor according to (5.2) 
7 VALIDATION OF THE RESULTS 
7.1 Identity 
The identity of maduramicin can be confirmed by co-chromatogrphy. 
A sample extract (5.2) is fortified by addition of an appropriate amount of calibration 
solution. The amount of added maduramicin should be similar to the amount of 
maduramicin found in the sample extract. 
Only the height of the maduramicin-peak should be enhanced after taking into account 
both the amount added and the dilution of the extract. The peak width, at half of the 
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height, must be within ± 10% of the original width of the maduramicin peak of the 
unfortified sample extract. 
7.2 Repeatability 
The difference between the results of two parallel determinations carried out on the 
same sample must not exceed xx % relative to the higher result for maduramicin 
contents. 
8 OBSERVATIONS 
8.1 The detector is used in visual scope at 520 nm and should give sufficient light energy. 
Noise preferabably should be < 1.10*5 AU (250nm, 600nm) 
8.2 A temperature of 92°C to 98°C is possible, high stability (± 1°C ) should be 
guaranteed 
8.3 The length of the teflon tube (e.g. lm ID 0.25 mm) between reagent-pump and mixing 
chamber and the length of the teflon tube (e.g. 3m ID 0.17 mm) between reactor and detector 
should be optimized if there are problems with bubbles 
8.4 Maduramicin is very toxic. LD50 = 33mg/kg (rat). 
8.5 Only area is allowed for calculation 
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Development and Validation of HPLC-methods for the official control of 
Coccidiostats and Antibiotics used as Feed Additives (SMT4-CT98-2216) 
Subtitle: 
Lab-name: 
Contact person: 
Task 4 COLLABORATIVE STUDY 
Date of analysis: [ 
Analyte: f 
Je-mail: 
fax: 
telephone: 
MADURAMICIN 
Sample code 
312233 
312247 
312264 
312307 
312331 
312334 
312357 
312359 
312362 
312367 
Unit 
Result 
(mg/kg) 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
Result 2 
(mg/kg) 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Annex 3 - Instructions for handling and analysis of the samples 
1. Storage 
Store the samples frozen until analysis 
2. Analysis 
Analyse the samples within 2 weeks after receipt 
ÜÄilliog 
• Feed samples: grind the feed samples with a mill equipped with a 1 mm screen 
• Premix: grind the premix sample with a mill equipped with a 0.5 mm screen. Take care of 
contamination of the milling equipment. 
After milling, store the samples at 4 °C (or frozen if the time between milling and analysis is longer than one 
week). 
4. Mixing nf thp tpst samples before weighing 
Mix the entire sample thoroughly 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Annex 4 - Questionnaire 
Laboratory: 
Contact person: 
Date(s) of analysis: 
Dilution factor of the samples: 
• Feed samples (specify for which feed samples): 
Premixture: 
Chromatographic conditions: 
• Column: 
• a As described in the method 
• D Other: 
• Mobile phase: 
• o As described in the method 
• D Other: 
• Flow-rate: m|/min 
• Injection volume : ul 
• Retention time of maduramicin: min 
Chromatograms: Please include representative chromatogramg of: 
• Blind positive feed samples 
• Blind blank feed sample 
• Premixture 
Please indicate the maduramicin peak with an arrow 
Recovery results: 
• Percentage recovery: % 
• Single/duplicate determinations: D single o duplicate 
• If duplicate, please give both percentages: % and % 
• Spiking level: mg/kg 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Remarks /Cornrrpnts f i f necessary, continue on another oaee) : 
Please complete this questionnaire and return it together with representative chromatograms to: 
Ing. JJ.M. Driessen 
RIKILT 
P.O. Box 230 
6700 AE Wageningen 
The Netherlands 
Fax+31-317417717 
Thank you for your cooperation ! 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Annex 5 - Special requests 
Volunteers are asked to do the following additional work: 
• post-column reaction with DMAB 
Conditions for post-column derivatisation : 
3.1 Methanol - HPLC grade 
3.8 Sulphuric acid, w (H2S04) = 95-97 % 
3.9 4-{dimethylaminoH)enzaldehyde (DMAB, C9HnNO) 
3.13 Methanol-sulphuric acid: 40 ml sulphuric acid (3.8) are given cautiously while stirring to 950 ml 
methanol (3.1). The solution is degassed prior to use in an ultrasonic bath (8.3) during 15 min. 
3.14 DMAB-solution: 60.0 g dimethylaminobenzaldehyde (3.9) are solved in 950 ml methanol (3.1). The 
solution is degassed prior to use in an ultrasonic bath (8.3) during 15 min. 
4.1.3 Post-column reactor (double pump or two single pumps) with mixing chamber, reaction coil of 
inert material (f.e. Teflon or Peek) for operation at 95 °C, 7.0 m with 0.33 mm ID and water bath 
or reactor oven for operation at 95 °C 
Flow rate of methanol-sulphuric acicknixture (3.13) 0.4 m|/min 
Flow rate of DMAB-solution (3.14) 0.4 m|/min 
Temperature of the post-column reaction 95 °C 
VIS-Detector after post-column reaction 600 nm 
Volume of injections 100 pi 
8.4 Post-column reaction 
If only one pump for the post-column reaction is available, the reagents 3.13 and 3.14 may be 
mixed (1 + 1 v/v). Since DMAB undergoes quick auto-oxidation resulting in darkening of the 
solution this has to be kept protected from light in an ice bath and has to be used within 24 h. 
Other conditions are not changed 
Please report the results in a copy of annex 4 and clearly describe your conditions, etc. if different from the 
above mentioned conditions. Please also include representative chromatograms. 
Thanks in advance for doing the additional work 
APPENDIX 2 
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c 
"o 
'E 
CD 
1— 
D 
"O 
CD 
O) 
E 
CN 
CD Ç 
E 
O 
c 
CD 
• o 
c 
CD 
E 
0 
Q . 
Q . 
D 
CO 
•o S 
0) -o 
C 0 
O) T" 
O o) il 
T CÛ 
_ CD •«* 
o p j i n 
* " CM~ CM 
0 > T -
cn w *-. 
CM CO 
co m 
00 f"- co 
CM CM 
CM m 
f - *>." » 
CM CM 
p 1 
0 •' ••.. 
CO CO U3 ' , ' ' 
tg i ß O) «g,. ;-.-*'. 
o î CM •*"..-•;;• 
1
 " • " • . • ' 
£ 
« 
3 
CM ri- O" 
«n », ». w 
CM CM c 
ra 
o 
s i n T Î u . 
,fr 00 " * O 
CN CM" "° 
3 
Su
m
 
o
f 
Sq
ua
re
s
 
•Ï * g 
CO CO « 3 = 
«M ». ». S « 
CM CM 3 "C 
o « 
co > 
00 00 
T - r*- o? 
csî CM" 
O 5K S» 
5 S S
 = ï * * | ! 
ra w c 
CO T * tM- — 
CM 
O 
CO 
II 
i n 
2 
E * * 
CM-' 
© - • -
p.-:-
<M- :' 
• * » 
CM 
m 
m 
o 
o * 
O) 
co 
co 
Oî 
« * • 
o" 
C (0 
« 'S! 
5 4= 
CD ra 
CQ CO 
co 
00 
CM 
w" 
3> 
00 
co" 
il 
O) 
co 
O 
o * , 
o 
<o-
i n 
CM 
p* 
W
ith
in
 
Sa
ch
ets
 
CM 
O) 
-ci-
in" 
O) 
CM 
CM 
75 
*•* 
o 
o 
CM 
CM 
in 
o" 
O) 
e 
Q. 
E 
10 
CO 
c 
o 
•3 
n 
> 
CO 
o CM 
O 
CO 
CO 
O 
75 
o 
* ï 
>» 
(0 
c 
< 
e 
o 
ra 
"> 
a> 
O 
i n 
00 
co 
co 
Tl"* 
c 
o 
0) 
2 
0) 
> 
o 
CM 
i n 
Tt-
T— 
CO* 
> O 
Tt 
Oi 
o 
CO 
m 
70 
> 
o 
Ûû 
> * 
• o 
13 
« t _ j 
CO 
>% 
•+—> 
CD 
C 
0 
O ) 
o E 
o X 
— • * o 
o CM w 
* " IC 
h-
o> o 
i n 
t*-
co CR 
• < * 
co 
b- «S. 
c 
o 
" E co 
CD «O O. 
»— m 
" O 
CO 
2 
E 
l O 
M— 
w
 «^ O) 
CO 
c 
O p, CM 
C IO-
CO 
- C 
'36 
73 in 
0 o« °°-
C 
CD 
P 
c_ CD 
Q_ ze'9 
i 
Idns 
0 
3 o » 
* ^ 2 Ö 
rk
ey
 
ch
et
l 
t A
ss
 
—* CO ü) 
" io" 
00 
^r* 
" i n 
i n 
^ 
i n 
CM 
i n 
'-O -' ' 
CO 33 V,y 
i n *r,\!-:' 
2 
ra 
3 
•e- er 
» c 
ra 
S 
• ^ « f r -
CD O 
i n "O 
Ä o © 
co & 
5,3
 
Su
m
 
Sq
ua
 
1 § o> 9> = 
So
ur
c 
Va
ria
i 
N 
n 
n 
10 
in c 
o S l 
E 
M 
CM 
O 
CO* 
II 
SN. -
m 
u . ' 
">5"' ' '.•• 
CMF; , t , 
C M , , ' . ; . 
* » ' r 
i n 
co 
o 
o " 
03 
00 
h-00 
N. 
o 
3> S i-s 
o ra 
r-CO CO 
co 
m* 
CM 
n 
N 
r-
n 
co 
N. 
00 
II 
NS 
os 
•c • 
u . 
co 
co 
o 
o " 
o 
o 
T — 
co 
co 
o 
5 Ta-l l -
in* 
CM 
m 
k o 
co 
o " 
a
m
pli
ng
 
e
via
tio
n
 
(0 O 
co 
o 
o 
o> 
ö " 
"H c 
a
lyt
ic;
 
via
tio
i 
e o 
< O 
OS 
Oï 
00 
^r 
T -
""" 
"ra <-• 
o 
CM 
m 
o> 
LO 
*1* CM 
m 
T -
cö 
co" 
c 
o 
o 
o 
> 
O 
co 
o 
O 
co* 
c 
'JE 
o5 
> 
O 
co 
co 
m 
co 
' t * 
75 
42 
> 
o 
ç 
'o 
E 
03 
•D 
CU 
O) 
O) 
E 
05 
CO 
c 
' E 
o 
c 
co 
> , 
• o 
3 
CO 
> > 
•4—» 
'<D 
c 
CD 
CD 
O 
E 
o 
-o CD 
4—> 
c 0 
E 
0 
Q. 
Q. 
D 
CO 
& 
m ^ " ' 
"O 
0 
L_ 
0 
O 
co 
o 
0 ) 
00 
r«-
t© 
tn 
-ft 
co 
CM 
T -
o 
z 
o 
sz 
o (9 
CO 
CO 
O) 
00 
CM 
CO 
O * 
l O 
CO 
O) 
co 
CM 
CO 
O)" 
CM 
e» 
w 
O 
i r-
ait 
o 
CM 
o> 
4 l 
(0 
< 
W 
o" 
W 
CM 
of 
1*-
i n 
CM 
O * 
CO 
co 
o * 
CD 
CO 
O 
O 
•'t 
o 
00 
•«fr 
0> 
CO 
o 
o> 
o 
$ 
•o-
c 
CM 
'O -, " 
£ 
re 
s 
er 
CO 
c (8 
0) 
£ 
'S 
"O 
i t . w 
i s 
So
ur
ce
 
o
f 
Va
ria
tio
n
 
c 
re 
CM 
O 
co" 
II 
ff» 
m 
• c 
2 co ., 
0D , 
CD-'-, 
io: -, 
©.•-;:-
00 
CO 
O 
O) 
-f 
O 
o 
co' 
Be
tw
ee
n
 
Sa
ch
et
s 
O 
O 
O) 
m 
CO 
m 
O) 
CO 
os" 
00 
II 
O) 
°l 
' E 
CO 
v -
CO 
© 
o 
o> 
CO 
T— 
co" 
W
ith
in
 
Sa
ch
et
s 
o 
o 
co 
!*-__ 
• ' t 
CO 
O) 
O 
CM 
co 
re 
O) 
o 
m 
i n 
m 
O) 
co 
o " 
Sa
m
pl
in
g 
De
vi
at
io
n
 
CM 
m 
co 
co 
o " 
An
al
yt
ica
l 
De
via
tio
n
 
m 
co 
CM 
CM 
c 
0) 
O) 
£ 
CD 
1 3 
cf» 
> 
O 
O) 
CO 
co 
CM 
CO 
N - " 
£ 
'JE 
> 
U 
m 
O) 
o 
oö 
O) 
00* 
2 
S"« 
> 
o 
c 
"o 
'E 
CO 
i _ 
" O 
CO 
O) 
E 
o 
m 
co g 
'E 
o 
c 
(0 
^ -o 
-o 0 
% g 
Q. 
Q. 
(/) 
>< 
'E 
0 
CD 
C 
0 
O) 
O 
E 
o 
1° 
o> 
00 
f» 
<o 
o 
CM 
T -
o 
z 
(0 
ü 
« (0 
CO 
CO 
Oi 
co 
co 
N -
i o 
CM 
W 
CO 
T l " 
00 
N-
(O 
o io 
co 
N-
U3 
ra 
n 
in 
< 
(0 
lO 
N -
CO 
00 
Tt 
o 
m 
o 
o 
o in 
o 
00 
(O 
o> 
CM 
CM 
m 
>» 
ra 
</> 
CO 
< 
" O 
c 
CM 
* 
111» 
«mal 
£ 
« 
3 
CP 
CO 
e 
ra 
'S 
Su
m
 
o
f 
Sq
ua
re
s
 
So
ur
ce
 
o
f 
Va
ria
tio
n
 
e 
ra 
co 
CM 
O 
CO" 
11 
o"» 
in 
' i — 
1' 
co 
co 
co in 
in 
T— 
Oi 
o 
N . 
CM 
Be
tw
ee
n
 
Sa
ch
et
s 
in 
o> 
CO 
co 
N 
o 
N 
co 
•«*• 
co" 
11 
èN 
O) 
°»l 
5 
o 
o 
o 
co 
co" 
o> 
o 
co 
00 
co 
TT 
c £ 
> ra 
* • ( 0 
00 
O) 
co 
00 
co 
N 
Oi 
co 
CM 
N 
N 
s 
o 
1-
m 
N i 
m 
N 
m 
CM 
Sa
m
pl
in
g 
De
vi
at
io
n
 
CO 
co 
CM 
CM 
CO 
CM" 
CM 
An
al
yt
ica
l 
De
via
tio
n
 
CO 
CO 
o> 
CO 
c 
0 
0) B 
© 
n 
> 
•<*• 
o> 
o> 
N 
m 
M-" 
C 
!E 
> 
CM 
in 
N 
CO 
TJ-
co 
co" 
w 
o 
*•• 
ÛÛ 
APPENDIX 3 
Sample codes 
>< 
TS 
3 
«A 
0> 
> 
'S 
!° b . O 
n ra 
ô u 
c 
o 
I 2 
3 TJ 
CO 
E 
0) 
£ 
• * ^ 
c 
Ä 
c 
«0 O. 
*ü 
ca 
a 
x: 
• • - > 
£ 
"O 
D. 
a 3 
«0 
in 
cu 
TS 
o 
o 
d) 
a. E 
(0 
(0 
0 ) 
'ë 
A a < 5 
0 ) 
g £ > 
Q 
< S 
0 ) 
o 
. Q 
D 
< 
2 
'5 A 
Q 
u . 
a> 
2 A 
Q 
< 
i I— 
2 A 
Q 
< 
S 
Q) 
3 
"*"' O 
< 
s 
3 
-*-• Q 
i 
X I 
T — 
J * 
C 
(0 
£ | 
O 
< 
s 
(0 
v -
2£. 
C 
ns £ 1 
o i 
A 
E "* Q . Q 
2 
(0 
E "f 
Q.Q 
s-1 2 
i n < 
t ' I 
c (0 
o. a 
m < 
^ " 2 
m < 
CM" S 
C (0 
s-« 
m <( 
CM" 5 
A 
E <-
co 
E *-
A l 
2 
T — 
10 
c CO 
CL 
Z S 
22 
rf p 
S c 
_^ i n 
CM 
CM 
CO 
• — 
,— 
o CO 
CM 
co 
T " 
CO 
O l 
CM 
CM 
CO 
T — 
CM 
m 
co CM 
co 
^ 
co 
CO 
CM 
CM 
CO 
T -
m 
co CM 
CM 
co 
T -
CM 
K 
CM 
CM 
CO 
CO 
O 
co CM 
CO 
T -
r>-CM 
CO 
CM 
CO 
T — 
CM 
0 0 
CM 
CM 
CO 
" 
CD 
TJ 
O 
O 
C 
CO 
D . 
'O 
• ë 
CO c o 
Q_ T -
O ) 
co CM 
CM 
r-
•<f 
• * 
CO 
CM 
r-
<r-
œ 
o> CM 
CM 
1 ^ 
T — 
TT-
h -
CO 
CM 
r^  
-^
co 
o 
co CM 
r^  
rr 
o> CM 
CM 
r-
CO 
c-CM 
CM 
N -
CO 
CO 
CM 
CM 
r-
CM 
T t 
CM 
CM 
h -
,— 
i>-
CM 
CM 
h -
" 
r-
- n 
o 
co CM 
CM 
CM 
CM 
i n 
r^  CM 
CM 
CM 
CM 
f -
co CM 
CM 
CM 
CM 
i n 
CD 
co CM 
CM 
CM 
r-
CO 
CM 
CM 
CM 
CM 
,_ 
Tj-
CO 
CM 
CM 
CM 
CM 
m CM 
CM 
CM 
CM 
CO 
CO 
CM 
CM 
CM 
CM 
f -
co 
co CM 
CM 
CM 
O 
in 
co CM 
CM 
CM 
CM 
CM 
CO 
m 
co CM 
co CM 
a> 
œ CM 
CM 
CO 
CM 
CO 
co 
co CM 
CO 
CM 
h -
co CM 
CM 
co CM 
CO 
m CM 
CM 
CO 
CM 
o> 
i n 
CM 
CM 
co CM 
T — 
0 0 
CM 
CM 
co CM 
o Tt" 
CM 
CM 
co CM 
• V 
l O 
CM 
CM 
CO 
CM 
O 
CD 
CM 
CM 
CO 
CM 
CO 
CM 
0 0 
CD 
CM 
CM 
CD 
CM 
• * 
m 
co CM 
CO 
CM 
r~ 
r-CM 
CM 
co CM 
O ) 
r~ CM 
CM 
CD 
CM 
t— 
co CM 
CM 
CD 
CM 
m 
m 
co CM 
CD 
CM 
0 0 
CD 
co CM 
CD 
CM 
o> 
o 
co CM 
CD 
CM 
co 
co CM 
CM 
co CM 
o 
m CM 
CM 
CD 
CM 
co 
CM 
TT 
CO 
CM 
CM 
N -
CM 
co 
N -
CM 
CM 
r~ CM 
^ 
•*r CM 
CM 
h -
CM 
O 
r-CO 
CM 
f -
CM 
r-
m CM 
CM 
r~ CM 
0 0 
co 
co CM 
r-CM 
co CM 
co CM 
r-CM 
o 
o 
co CM 
r-CM 
co l-~ 
CM 
CM 
r*-CM 
CM 
o> CM 
CM 
r-CM 
r~ 
CM 
m 
o> CM 
CM 
o> CM 
m 
CM 
co CM 
o> CM 
CM 
CM 
co CM 
O l 
CM 
CM 
• > * • 
co CM 
o> CM 
m 
o 
co CM 
O ) 
CM 
co 
* co CM 
O ) 
CM 
CD 
• * 
CM 
CM 
O ) 
CM 
CM 
CD 
CM 
CM 
O) 
CM 
• -
co 
co CM 
œ CM 
o 
co 
co CM 
a> CM 
C» 
CM 
CO 
m 
co CM 
o 
co 
m 
~^ CO 
CM 
o 
co 
o 
o> CM 
CM 
o 
co 
0 0 
~^ co CM 
o 
co 
co 
T " " 
co CM 
o 
co 
c» 
CM 
co CM 
o 
co 
T T 
r~ CM 
CM 
o 
co 
•* CM 
co CM 
o 
co 
0 0 
CM 
co CM 
o CO 
co 
O ) 
CM 
CM 
o 
co 
o 
co 
1 ^ 
• t 
CM 
CM 
T — 
co 
• * 
CD 
CM 
CM 
T -
co 
h -
CD 
co CM 
^ co 
t>-
o CO 
CM 
T * 
CO 
•<r 
co 
co CM 
^ CO 
CM 
co 
co CM 
T -
co 
~^ co CO 
CM 
~^ co 
o> i n 
co CM 
T — 
co 
co 
co CM 
CM 
T -
co 
N -
m 
co CM 
T — 
co 
V -
co 
CD 
CM 
co CM 
CM 
CO 
o 
CD 
co CM 
CM 
CO 
i n 
co 
co CM 
CM 
co 
T -
CM 
co CM 
CM 
co 
CM 
N -
co CM 
CM 
co 
m 
•«c CM 
CM 
CM 
co 
CM 
T — 
CO 
CM 
CM 
CO 
N . 
' * CO 
CM 
CM 
co 
o> 
• * 
co CM 
CM 
co 
co 
co CM 
CM 
CM 
co 
CM 
co 
m 
0 0 
CM 
CM 
co 
co 
• * 
• * 
CM 
CM 
co 
co 
co 
<•!• CM 
CM 
co 
co 
TT 
o 
co CM 
CO 
CO 
CM 
O 
CO 
CM 
CO 
CO 
a> 
0 0 
CM 
CM 
co 
co 
m 
m CM 
CM 
co 
co 
CD 
co CM 
CM 
co CO 
*— • — 
co CM 
co 
co 
co 
»T 
CM 
CM 
CO 
co 
co 
co 
i n 
co CM 
CM 
i n 
co 
co 
CD 
co CM 
m 
co 
co 
i n 
co CM 
m 
co 
CM 
co 
co CM 
i n 
CO 
co 
m CM 
CM 
m 
co 
0 0 
• f 
CO 
CM 
m 
co 
o 
T -
CO 
CM 
m 
co 
T»-
—^ co CM 
m 
co 
•<r 
co CM 
CM 
i n 
co 
o 
CM 
co CM 
i n 
co 
m 
co 
o m 
xf ^t-
co co 
CM CM 
CD 0 0 
CO CO 
N - O 
o> ^r 
CM CM 
CM CM 
CO co 
CO CO 
CO CO 
co "<r 
co co 
CM CM 
CO 0 0 
CO CO 
O C» 
h- co 
CM CO 
CM CM 
CO 0 0 
CO CO 
r~ 0 5 
T - ^ 
CO c o 
CM CM 
CO 0 0 
CO c o 
c o e n 
0 0 c o 
CM CM 
CM CM 
CD 0 0 
c o c o 
oo a > 
m c o 
CM CO 
CM CM 
c o oo 
c o c o 
T - T»" 
m co 
co co 
CM CM 
co oo 
co co 
co co 
T - CO 
co co 
CM CM 
CD 0 0 
co co 
•»- 0 0 
o o CM co CM CM 
co 00 
co co 
co 00 
co co 
APPENDIX 4 
Maduramcyin reference standard profille 
A U G - e e - e e i 3 > i e F R O M . A L P H A R M A I D . PACE 
08 AUG '00 19:16 
® ALPHARMA 
Animal Health Division 
TECHNICAL CENTER 
1DUGGAR DRIVE 
WILLOW ISLAND, WV 26134-9711 
Phone: (304)66*4191 
Fax: (304)665-41*7 
Certificate of Analysis 
NAME: Maduranuon DATE- Aupist 3.200Ç 
Specifications 
Lot No: 
Purity: 
Standard Type: 
Reference Nor 
Expiration Date: 
Drying Conditions: 
1 Storage Conditions: 
AC9745-1C 
95.9% (byHPLQ 
Secondary Standard 
TC4122 
August 2002 
Dry at 60*C, 28 mm Hg, for three hours prior to use. 
Store in dark container, at < 8°C 
Analyzed By: V ^ M C f (Mf*** 
JcfcnE Fryman / 
Released By:. 
J.Henry 
Analytical Development 
TCSUU2 Revision U 
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Annex 2 
CANFAS 
i Development and Validation of HPLC-methods for the official control of 
IÇoccidiostats and Antibiotics used as Feed Additives (SMT4-CT98-2216) 
- - . - • _ _ _ _ - - . . . . j 
Subtitle: 
Lab-name: 
Contact person: 
Date of analysis: 
Analyte: 
Task 4 COLLABORATIVE STUDY 
e-mail: 
fax: 
telephone: 
MADURAMICIN 
Sample code 
172238 
172242 
172269 
172271 
172273 
172294 
172298 
172303 
172344 
172371 
Unit 
Result 
(mg/kg) 
2,51 
4,94 
0 
4,97 
2,67 
4,75 
9,38 
4,71 
0 
9,41 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
514 
Result 2 
(mg/kg) 
503 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Annex 4 - Questionnaire 
Date(s) of analysis £& . •/-/ • 2^ooo t 
dilution factor of the samples; 1 f / ) 
• Feed samples (specify for which feed samples): ! L.... .f.. .{.~?..^r../.. 
ChromatoprflphiC cnnHitinn«;: 
• Column: 
• % As described in the method 
• G Other: 
• Mobile phase: 
• X A s described in the method 
• D Other: 
• Flow-rate: Qà.7..... ml/min 
• Injection volume: ..-££\...ul 
• Retention time of maduramicin:"?.//.... min • ' 
Chromatograms; Please include representative chromatoerams of: 
• Blind positive feed samples 
• Blind blank feed sample 
• Premixture 
Please indicate the maduramicin peak with an arrow 
toverv results; 
• Percentage recovery: r.f!'.7% 
• Single / duplicate determinations: D single X d u P | i c a t e 
• If duplicate, please give both percentages: ?.?.'* % and .<?.<?,?% 
• Spiking level: ....-£.... mgAg 
Zfûl^, Uvel 2,rn+f/if Ptec. rec&ixs« ^ ^ , 4oo/C 
1 
I-
D-7000 HSM: MAD./ SAL./ MON. Series: 0559 
Sample Name: Premix 
Sample Description: 
Analyzed: 28.11.00 15:35 Reported: 30.11.00 10:38 
Processed: 30.11.00 10:38 
Data Path: C:\Win32App\HSM\MADURAMYCIN\DATA\0559\ 
Application: MAD./ SAL./ MON. Vial Number: 4 
Injection from this vial: 1 of 1 Vial Type: UNK 
Volume: 50,0 ul 
Sample Description: 
Chrom Type: HPLC Channel 
% 
SS 
c 01 
2,0 • 
1,5 
1,0 
0,5 
0,0-
-0,5 
TV 
1
 I ' I ' I ' I ' [ ' I ' I ' I ' I ' | ' I ' I ' I ' I ' | ' I ' I ' I ' I ' | ' I ' [ • | ' | ' | ' | ' | ' | ' | ' I ' | i | i | ' | i I 
10 15 20 
Retention Tine (min) 
25 30 35 
Acquisition Method: Maduramycin 
Column Type: Hypersil BDS 
Pump A Type: L-7100 
Peak Quantitation: AREA 
Calculation Method: EXT-STD 
Solvent A: MeOH/Buffer 
Sample Amount: 1,000 
Scale Factor 1: 1,000 
Name 
Maduramycin 
RT 
17,91 
24,81 
Area 
475 
37452 
37927 
Height 
9 
794 
803 
Cone 1 
0,000 
1,179 
1,179 
BC 
BB 
BB 
Peak rejection level: 0 
HPLC-pump: 0,4ml/min 
Reagent-pump: 0,4ml/min 
Collumn-temperature: 40°C 
Reactor-temperature: 95°C 
5l7000 HSM: MAD./ SAL./ MON. Series: 0560 
Sample Name: 1 7 2 2 3 8 
Sample D e s c r i p t i o n : 
Analyzed: 2 8 . 1 1 . 0 0 22 :11 
D a t a P a t h : C:\Win32App\HSM\MADURAMYCIN\DATA\0560\ 
A p p l i c a t i o n : MAD./ SAL./ MON. 
- e j e c t i o n from t h i s v i a l : 1 of 1 
Sample D e s c r i p t i o n : 
R e p o r t e d : 3 0 . 1 1 . 0 0 10 :46 
P r o c e s s e d : 3 0 . 1 1 . 0 0 10 :45 
1 
«0 
S 
2,0 1 
hs-1 
1,0 
0,5-4 
0,0 
-0,5 
Vial Number: 13 
Vial Type: UNK 
Volume: 50,0 ul 
Chrom Type: HPLC Channel : 1 
J±> 
o 
' I I I M i M M I ' I I I l I i I • I ' I ' I ' I ' I ' I ' I ' I ' I ' I ' I ' I ' ) ' I ' I ' I ' I ' I ' I ' I ' P I ' | ' I ' I ' I ' I ' | 
5 10 15 20 25 30 35 
Retention Time (min) 
A c q u i s i t i o n Method: Maduramycin 
column Type: Hypersil BDS 
^ P A Type: L-7100 
eak Q u a n t i t a t i o n : AREA 
c a l c u l a t i o n Method: EXT-STD 
Name 
I a duramycin 
RT 
24 ,49 
2 7 , 1 1 
3 0 , 5 3 
Area 
16924 
3760 
835 
21519 
Solvent A: MeOH/Buffer 
Sample Amount: 1,000 
Scale Factor 1: 1,000 
Height 
370 
103 
13 
486 
Cone 1 
0,549 
0,000 
0,000 
0 , 5 4 9 
BC 
BB 
BB 
BB 
e a k r e j e c t i o n l e v e l ; 
^
P LC-pump: 0 ,4ml /min 
„
e agen t -pump: 0 ,4ml /min 
-Q-Uumn-temperature : 40°C 
« a c t o r - t e m p e r a t u r e : 9 5 ° c 
Paae I n d i c a t o r 1 / 5 
D-7000 HSM: MAD./ SAL./ MON. Series: 0560 
S a m p l e Name: 1 7 2 2 6 9 
Sample Description: 
Analyzed: 28.11.00 23:23 Reported: 30.11.00 11:03 
Processed: 30.11.00 11:03 
Data Path: C:\Win32App\HSM\MADURAMYCIN\DATA\0560\ 
Application: MAD./ SAL./ MON. Vial Number: 15 
Injection from this vial: 1 of 1 Vial Type: UNK 
Volume: 50,0 ul 
Sample Description: 
Chrom Type: HPLC Channel : 1 
% 
m 
S 
2,0 
1,5-3 
1,0 
0,5 
0,0 
-0,5 
» r -
l / l CM 
~P^ 
I ' I ' I ' I ' | ' I ' I ' I ' I ' | ' I ' I ' I ' I ' | ' I ' I ' I ' I ' [ ' I ' I ' I ' I ' | ' I ' I ' I ' I ' I ' I ' I ' I ' I ' I 
10 15 20 
Retention Time (min) 
25 30 35 
Acquisition Method: Maduramycin 
Column Type: Hypersil BDS 
Pump A Type: L-7100 
Peak Quantitation: AREA 
Calculation Method: EXT-STD 
Name RT Area 
25,83 
27,11 
31,45 
348 
2273 
1599 
4220 
Height 
6 
60 
14 
80 
Solvent A: MeOH/Buffer 
Sample Amount: 1,000 
Scale Factor 1: 1,000 
Cone 1 
0,000 
0 ,000 
0 ,000 
0,000 
BC 
BB 
BB 
BB 
Peak rejection level: 0 
HPLC-pump: 0,4ml/min 
Reagent-pump: 0,4ml/min 
Collumn-temperature: 40°C 
Reactor-temperature: 95CC 
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Annex 2 
CANFAS 
: Development and Validation of HPLC-methods for the official control of 
jÇoccidiostats and Antibiotics used as feed Additives (SMT4-CT98-2216) 
Subtitle: 
Lab-name: 
Contact person: 
Date of analysis: 
Analyte: 
Task 4 COLLABORATIVE STUDY 
e-mail: 
fax: 
telephone: 
MADURAMICIN 
Sample code 
222252 
222263 
222267 
222275 
222280 
222287 
222337 
222341 
222350 
222365 
Unit 
Result 
(mg/kg) 
2,64 
2
-
5 7 
4,87 
<1 
<1 
9,44 
5,52 
5,08 
5,04 
9,52 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
485 
Result 2 
(mg/kg) 
510 
CANFAS COLLABORATIVE STUDIES OCTOBER 2 0 0 0 - MADURAMICIN 
Annex 4 - Questionnaire 
Datefs) of analysis: Q.O.LL&S./.Zh. 
^^tJooiactornfthftsamplfty _ 
* Feed samples (specify for which feed samples): .X..T7..!. 
Premixture: 17..ÜJ.Q. 
Chromatograph^ mnrftinns; 
• Column: 
• £ßs described in the method 
• D Other: >., 
* Mobile phase: 
• ^ A s described in Ihe method 
• D Other: 
Flowrate: ....Cj.fi rtH/rnn 
* Injection volume:.&0....\H 
Retention time of maduramicin: fe S.. min 
^^JOmalQgramg- p l q ^ e include representative chromatograms of: 
Blind positive feed samples 
Blind blank feed sample 
' Premixture 
ease /hdfcate the maduramicin peak with an arrow 
Percentage recovery: l 9 . l . % 
Single / duplicate determinations: a single ^duplicate 
f duplicate, please give both percentages: .7.3. % and i < S % 
Spiking level:.%.{.... mg/kg 
NEW TIMED EVENTS FROM MADURAMI 
******* EXTERNAL STANDARD TABLE ******* 
******************** 12-08-2000 11:55:16 Version 5.1 ********************** 
* Sample Name: prov nr 4 Data File: D:madu012 
* Date: 11-23-2000 21:42:21Method: MADURAMI 12-06-2000 09:00:18 # 847 * 
* Interface: 0 Cycle# : 1 ,, Operator ann Channel#: 0 Vial#: * 
* Starting Peak Width: 50 Threshold: .05 Area Threshold: 50 * 
*************************************************************************** 
Starting Delay: 0.00 Ending retention time: 32.00 
Area reject: 50 One sample per 0.200 sec. 
Amount injected: 80.00 Dilution factor: 1.00 
Sample Weight: 1.00000 
PEAK RET 
NOM TIME 
CONCENTRATION i n 
u g / m l 
NORMALIZED 
CONC AREA 
AREA/ 
HEIGHT HEIGHT EL 
REF 
PEAK 
t DELTA 
RET TIME CONC/AREJ 
TOTAL AMOUNT 
PEAKS NOT FOUND IN THIS RUN 
NAME ADJUSTED RET.TIME. 
m| 26.54 REFERENCE PEAK mad 
Data File = D:madu012.PTS Printed on 12-08-2000 at 11:55:20 
Start time: 0.00 min. Stop time: 32.00 min. Offset: 
Low Value: 0 uv High Value: 6102 uv Scale factor: 
0 mv. 
1.0 
f ScLMoie. 2.2221-5 f 
• • (22; 
NEW TIMED EVENTS FROM MADÜRAMI 
******* EXTERNAL STANDARD TABLE ******* 
******************** 11-30-2000 08:29:22 Version 5.1 ********************** 
* Sample Name: prov nr 1 Data File: D.-madnn^ i * 
* Date: 11-25-2000 20 :54:40Method: .MADURAMI 11-30-2000 08:27:00 # 806 * 
* Interface: 0 Cycle# : 1 •>,. Operator arm Channel# : o Vial#: * 
* Starting Peak Width: 50 Threshold: .05 Area Threshold: 50 * 
*************************************** **********************:" ' Starting Delay: 0.00 
^ a reject: 50 
Jroount injected: 80.00 
Sample W e i g h t : 1 .00000 
PEAK R B T 
"OM TIME 
PEAK CONCENTRATION in NORMALIZED 
NAME ug/ml CONC 
r * * * * * * * * * * * * * * 
Ending retention time: 32.00 
One sample per 0.200 sec.' 
Dilution factor: 1.00 
AREA/ 
HEIGHT HEIGHT BL 
REF 
PEAK 
* DELTA 
RET TIME CONC/AREA 
1
 26.218 mad 0.6149 100.0000% 3589S S30 67.7 1 1.7132B-05 
TOTAL AMOUNT 0.6149 
©TART TIME= 25.106 START HEIGHT- 69 
Ä STOP TIME= 27.442 STOP HEIGHT= 104 
^ =
 32658 
°LT> AREA FOR PEAK# 1 = 35894.98 NEW AREA= 32658 
JLE HEIGHT FOR PEAK # 1 = 529.881 NEW HEIGHT= 483.9104 
^^INT AREA REPORTS FOR NEW TABLES. 
******* EXTERNAL STANDARD TABLE ******* 
******************** 11-30-2000 08:30:08 Version 5.1 ********************** 
* Sample Name: prov nr 1 Data File: D.-marinn/n * 
*
 Date: 11-25-2000 20:54:40Method: MADURAMI 11-30-2000 08:27:00 # 806 * 
4 ^terface: 0 Cycle#: 1 Operator arm Channel*: 0 ^ Vial#: 
Stc ' * '" 1--1-1 
-">-crrace • o Cycle#: 1 Operator aim Channel#: 0 Vial#.-
. Starting Peak Width: 50 Threshold: .05 Area Threshold: 50 * 
************************************************************************** 
?tarting Delay- 0.00 Ending retention time: 32.00 
JT^ a reject- 50 0 n e sample per 0.200 sec. 
r O U n t injected: 8 0.00 Dilution factor.- 1.00 
sample Weight: 1.00000 
^ T I H E 
1 26.2X8 
PEAK 
NAME 
mad 
TOTAL AMOUNT 
CONCENTRATION in 
ug/ml 
0.5S9S 
0.5595 
NORMALIZED 
CONC 
100.0000% 
AREA/ 
AREA HEIGHT HEIGHT BL 
32658 484 67.5 1 
REF 
PEAK 
1 
% DELTA 
RET TIKE 
0 
CONC/AREA 
1.7132E-05 
aJa File = D:madu041.PTS 
^
art time: 
Printed on 11-3 0-2000 at 08:30:10 
0.00. min. Stop time: 32.00 min. Offset: 
0 uv High Value: -4119 uv Scale factor: 
L , $ .....A. 
.1..-
0 mv. 
1.0 
jScL»»ple 2222 b 2.) 
(ID. 
NEW TIMED EVENTS FROM MADURAMI 
******* EXTERNAL STANDARD TABLE ******* 
******************** 11-30-2000 08:33:57 Version 5.1 ********************** 
* Sample Name : prov nr 3 Data File: D:madu043 
* Date: 11-25-2000 22 : 02 :03Method: MADURAMI 11-30-2000 08:27:00 # 806 * 
* Interface: 0 Cycle#: 1 •„ Operator arm Channel#: 0 Vial#: * 
* Starting Peak Width: 50 Threshold: .05 Area Threshold: 50 * 
*************************************************************************** 
Starting Delay: 0.00 Ending retention time: 32.00 
Area reject: 50 One sample per 0.200 sec. 
Amount injected: 80.0 0 Dilution factor: 1.00 
Sample Weight: 1.00000 
PEAK RET PEAK CONCENTRATION in 
NCW TIME NAME ug/ml 
1 26.208 mad 0.9352 
TOTAL AMOUNT - 0.93S2 
NORMALIZED 
CONC 
100.0000% 
AREA 
54S86 
AREA/ 
HEIGHT HEIGHT BL 
842 64.8 1 
REF 
PEAK 
1 
% DELTA 
RET TIME 
0 
CQNC/ARE) 
1.7132E-I 
^TART TIME= 25.078 START HEIGHT= 130 
STOP TIME= 27.829 STOP HEIGHT= 98 
AREA = 57044 
OLD AREA FOR PEAK# 1 = 54586.44 NEW AREA= 57044 
OLD HEIGHT FOR PEAK # 1 = 841.9047 NEW HEIGHT- 821.1857 
REPRINT AREA REPORTS FOR NEW TABLES. 
******* EXTERNAL STANDARD TABLE ******* 
******************** 11-30-2000 08:34:38 Version 5.1 ********************** 
* Sample Name: prov nr 3 Data File: D:madu043 
* Date: 11-25-2000 22:02:03Method: MADURAMI 11-30-2000 08:27:00 # 806 * 
* Interface: 0 Cycle#: 1 Operator ann Channel#: 0 Vial#: * 
* Starting Peak Width: 50 Threshold: .05 Area Threshold: 50 * 
*************************************************************************** 
Starting Delay: 0.00 Ending retention time: 32.00 
Area reject: 50 One sample per 0.20 0 sec. 
Amount injected: 80.00 Dilution factor: 1.00 
Sample Weight: 1.0 0000 
PEAK RET PEAK CONCENTRATION in NORMALIZED AREA/ REF 
TIME NAME ug/ml CONC AREA HEIGHT HEIGHT BL PEAK 
% DELTA 
RET TIME CONC/ARE» 
1.7132E-0! 1 26.208 mad 0.9773 100.0000% 57044 821 69.5 1 
TOTAL AMOUNT 
Data File = D:madu043.PTS Printed on 11-30-2000 at 08:34:40 
Start time: 0.00-min. Stop time: 32.00 min. Offset: 0 mv. 
Low Value: 0 uv High Value: 4036 uv Scale factor: 1.0 
iû,mç,H TôTîôT] 
******* NEW TIMED EVENTS FROM «*&*}**
 STANDARD TABLE 
******* ff^f^O J:03:30 Version 5.1 ********************** 
******************** 11-29-200U xo.uj
 nat.a File: D,-madu024 
* Sample Name: premix 1 .
 d MADURAMI 11-29-2000 14:41:00 # 801 * 
* Date: 11-24-2000 ?4 :26:35Method^^ ^
 c h a n n e l # ; 0 v i a l # ; 
* Interface: 0 Cycle« : l
 Tv,«shold: -05 Area Threshold: 50 * 
* Starting Peak Width: 50 ^^=^^*********************************** 
"- ""*********** Ending retention time: 32.00 Starting Delay: 
•Area reject: 
Amount inj ected: 
Sample Weight : 
0.00 
50 
80.00 
1.00000 
One sample per 0.200 sec. 
Dilution factor: 1.00 
AREA/ 
PEAK R E T
 ÎEMC CONCENTRATION i» " " " J " " 0 ^ HEIGHT HEIGHT BL PEAK 
*TOM TIME KÄME ug/,rol 
1
 26.224 mad 
TOTAL AMOONT » 
'Ï.SS66 100.0000% 60803 » 0 65.« X 
0.9SS6 
* DELTA 
RET TIME CONC/AREA 
1..5732E-05 
153 
^TART TIME* 24.714 START HEIGHT» 
#TOP TIME= 28.055 STOP HEIGHT-
^EA = 65598
 2 7 NEW AREA- 65598 
OLD AREA FOR PEAK# 1 - 6 0 8 ^ ' / = NEW HEIGHT- 938.3638 
°LD HEIGHT FOR PEAK # 1 - ?Hl*l%S 
REPRINT AREA REPORTS FOR NEW T A B L ^ ^ ******* 
******* EXTERNA!« &J-/u*i"~r^.rÄ„_H _n e i ********************** 
******************** 11-29-2000 16.u«.^ nat.a File: D:madu024 * 
* Sample Name: premix 1 .,CVI_hod. MADURAMI 11-29-2000 14:41:00 # 801 * 
* DatS: 11-24-2000 04:26:35Hethod; W » " J ^ Channel*: 0 Vialt: incite: 11-24-^uuu
 v
^-"~ •- nnerator ann cnannej.»-. u 
* Interface: 0 Cycle#: 1 ~J
 h o l d : .05 Area Threshold 
* Starting Peak Width: 50 .™™S************************* 
*************************** Ending retention Starting Delay: 0.00 
•^ea reject: 50 
Amount injected: 80'î?,nnn 
Sample Weight: !..00000 
* 
50 * 
**************** 
Ending retention time: 32.00 
O e sample per 0.200 sec. 
Dilution factor: 1.00 
»BAX RET 
"* TIME 
PEAK 
NAME 
CONCESTRATIOH in 
ug/ml COHC 
AREA/ 
M B A HEIGHT HEIGHT BL 
REP 
PEAX 
* DELTA 
RET TIME CONC/AREA 
1
 26.22« mad 
TOTAL AMOONT -
1.0320 
1.0320 
100.0000* 65B98 
938 69.9 1 1.S732E-0S 
-» S0**< 
-
 a
 P i l e = D:madu024.PTS P r i n t e d on 
1 1 - 2 9 - 2 0 0 0 a t 1 6 : 0 4 : 0 7 
s t a r t t i m e : 
J
°w V a l u e : 
32.00 nun. Offset: 0.00 min. Stop time: • Scale factor: 
,ti _v. t r a î n e : J-U 3° " 
0 mv. 
1.0 
0 uv High V a l u e 
"Premî IK 
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Annex 2 
CANFAS 
•Development and Validation of HPLC-methods for the official control of 
jÇoccidiostats and Antibiotics used as Feed Additives (SMT4-CT98-2216) 
Subtitle: 
Lab-name: 
Contact person: 
Date of analysis: 
Analyte: 
Task 4 COLLABORATIVE STUDY 
e-mail: 
fax: 
telephone: 
MADURAMICIN 
Sample code 
232237 
232240 
232253 
232254 
232259 
232260 
232281 
232299 
232336 
232353 
Unit 
Result 
(mg/kg) 
12,07 
3,18 
5,91 
6,76 
6,49 
6,44 
3,28 
<0,39 
12,9 
<0,39 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
506,91 
Result 2 
(mg/kg) 
501,15 
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Annex 2 
CANFAS 
! Development and Validation of HPLC-methods for the official control of 
jÇoccidiostats and Antibiotics used as Feed Additives (SMT4-CT98-2216) 
Subtitle: 
Lab-name: 
Contact person: 
Date of analysis: 
Analyte: 
Task 4 COLLABORATIVE STUDY 
e-mail: 
fax: 
telephone: 
MADURAMICIN 
Sample code 
262250 
262261 
262266 
262268 
262277 
262279 
262309 
262354 
262355 
262368 
Unit 
Result 
(mg/kg) 
4,0 
3,3 
4,0 
0,8 
6,2 
7,5 
2,2 
O-7 
3,7 
1,9 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
Result 2 
(mg/kg) 
340,8 
ih 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Annex 4 - Questionnaire 
Date(s) of analysis: tlfZj.fi). 
I3ülJttQaiactQrQftheï;amplfl,';; 
* Feed samples (specify for which feed samples): / r£ fc* . 
* Premixture: !\^i~.. 
^^QmajQgraphic renditions: 
Column: 
• D As described in the method 
. o Other: 3t.{#&.'..£k*#. #£•£ — 
• Mobile phase: 
• &As described in the method 
• D Other: 
flow-rate: ..Q.p. ml/min T*v fosér cjbs~~- K * ^ ^ t - * u - ^^CL 
* Section volume: fS$L.!jtP 
detention time of maduramicin: T.?^. min 
^ P a t o g t a m s ; Please inclue r*>prps«ntatiVp chromatograms of: 
Blind positive feed samples 
Bll
'nd blank feed sample 
^emixture 
ase lnd
'cate the maduramicin peak with an arrow 
*
eC0i
«QUesüits; 
Rentage recovery: ?9...% 
lnfi 'e/ duplicate determinations: nTsingle a duplicate 
duP''cate, please give both percentages: % and % 
S
»*ing level: . . X . . mg/kg 
2,6^3^? Chromatogram 
Sample Name : A3011167 
FileName : C:\TC4\CANFAS\MADORA~1\DATA037.RAW 
Method : 
s t a r t Time : 0.00 min End Time : 28.00 min 
Scale Factor: 0.0 Plot Offset: 59 mV 
Sample I : 19 Page 1 of 1 
Date : 06/03/01 09:37 
Time of Injection: 06/12/00 07:38 
Low Point : 59.04 mV High Point : 68.71 mV 
Plot Scale: 9.7 mV 
— oo 
«3 l O 
1 1 1 
OO OO O ro*^- — 
r~ K~) cri uncrc*!-
r^ o o o o C T J C T J O 
1 II 1 1 1 1 1 1 1 
o-> 
o 
CNi 
CN1 
1 
o 
CNJ 
1 
• ö — O 
T - C N I 
CXTNCNi 
1 1II 
10 12 
TJÏÏÏTI 
14 nrn 16 18 20 22 
lll|llll|ll!l(l Jjf' 
9 4 9 f i 
-p/y^O^ Chromatogram 
lömple Name 
"i-UNaaie 
'ethod 
' t a r t Time 
fcaie f a c t o r : 
M 0 1 U 7 0 C:\TC4\CANFAS\MADURA-1\DATA051.RA« 
0.0Q min 
0.0 
End Time : 28.00 min 
Plot Offse t : 61 mV 
Sample #: 26 Page 1 of 1 
Date : 06/03/01 09:38 
Time of I n j e c t i o n : 06/12/00 14:34 
Low Point : 60.12 mV High Poin t : 10.65 mV 
Plot Sca le : 9.9 mV 
- n o in — r~. 
vri i< r^ 
II II II 
00 
I I 
t o 
cri 
II 
fOOCOä-ro 
c r i a c ö - ^ 
1 1 1 1 1 
CNCS1 
1 1 
1 ^ 
i r i 
1 
t o 
CM 
i 
12 1 4 
Time [min] 
TTjTTTTJTTn 
18 20 
[1I!I|IIII|IIII|IHI|IIII| 
22 24 26 
~zc2/5.£y Chromatogram 
Sample Name 
FileName 
Method 
Start Time 
Scale Factor: 
A3011172 
C:\TC4\CANFAS\MADURA-1\DATA055.PAK 
0.00 min 
0.0 
End Time : 28.00 min 
Plot Offset: 61 mV 
Sample »: 2S Page 1 of 1 
Date : 06/03/01 09:33 
Time of Injection: 06/12/00 16:33 
Low Point : 61.08 mV High Point : 70.46 mV 
Plot Scale: 9.4 mV 
OCDCn (NI OO ^Njr~-40CNI ao roo oo 
•^OOCNJ en u3 c^novooo *r ojr-^ x> 
<£>ibr-^  t-.' od OXTicrioö - - cvicsj f> 
*— • — > — •.— •— — * — - — C N I t N CNt f\JC\ CNJ 
IM I I I I ! I II I I II II I 
••a- i n 
°? "1 
Csi CM 
I ; 
1 0 - -
CNfsJ 
I II 
70.0 1 
69.5-
69.0-
68.5-
68.0-
67.5-
67.0-
66.: 
> 
JL 66.1 
65.: 
65.C 
64.1 
64.1 
63.5-
63.1 
62. 
62.' 
61.£ 
et 
>-
2 4 6 8 10 12 14 
l l | I M I | l l l l | l l l l | l l l l | l l 
16 18 20 
i ! i i | i i i i | i i i i | i i i i | i i i i | i i i ! | r 
22 24 26 
Pt CYVM X Chromatogram fn£j 
S a mPle Name ; 
FUeName 
M
«thod 
f t a r t Time .' 
S c a l e Facto---
A3011175 
C: \TC4\CANFAS\MADURA-1\DATA021 .RAW 
MADUH.MTH 
0.00 min End Time : 28.00 min 
0 .0 P lo t Offse t : 58 mV 
Sample #: 11 Page 1 of 1 
Date : 06/03/01 11:23 
Time of I n j e c t i o n : 05/12/00 23:42 
Low Point : 57.50 mV High Point 
P lo t S c a l e : 12.2 mV 
CT) OOCN O — r T J O r o —- OO 
•^> O l ' « - K1DCJOCO l O CN 
69.75 mV 
69.0-q 
14 16 
Time [min] 
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Annex 2 
CANFAS 
: Development and Validation of HPLC-methods for the official control of 
iÇoccidiostats and Antibiotics used as Feed Additives (SMT4-CT98-2216) 
Subtitle: 
Lab-name: 
Contact person: 
Date of analysis: 
Analyte: 
Task 4 COLLABORATIVE STUDY 
e-mail: 
fax: 
telephone: 
MADURAMICIN 
Sample code 
272234 
272241 
272257 
272276 
272278 
272292 
272300 
272323 
272338 
272370 
Unit 
Result 
(mg/kg) 
not detectable 
9,56 
4,77 
not detectable 
5,21 
4,90 
2,65 
2,67 
4,73 
9,56 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
456,1 
Result 2 
(mg/kg) 
474,4 
ï^ 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADÜRAMICIN 
Annex 4 • Questionnaire 
Date(s) of analysis: A^A^..ÀQ...Ali..-:..M.., &.£#£?. 
Dilution factor of the samples: 
• Feed samples (specify for which feed samples): QiUr.....£A.Y&p.l.C.A. f"..77..<f.. 
Premixture: f~Ad 
Chromatographie conditions: 
• Column: 
• X ^ s described in the method 
• D Other: 
• Mobile phase: 
• y(fis described in the method 
• D Other: 
. Flow-rate: fy#..ml/min hi.fci'ie f)k*se~ Û K ^ ^ V * J / m r H V**,'Ht\ 
• Injection volume: ....•£#...ul rCfl-(j€k.f 
• Retention time of maduram icV^Xmin Ytatk* 0*** i etuf4.ra.4urc ; q ?>c 
fal*f«.Ur lotKik ) 
Chromatograms: Please inchf^^ representative chromatPgramS Oft 
• Blind positive feed samples 
• Blind blank feed sample 
• Premixture 
Please indicate the maduramicin peak with an arrow 
fiexovery results: 
• Percentage recovery: 492^1% 
• Single / duplicate determinations: ^ single D duplicate 
• If duplicate, please give both percentages: % and % 
• Spiking level: Or....vL mgAg 
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Annex 2 
CANFAS ZI 
: Development and Validation of HPLC-methods for the official control of 
IÇoccidiostats and Antibiotics used as Feed Additives (SMT4-CT98-2216) 
Subtitle: 
Lab-name: 
Contact person: 
Date of analysis: 
Analyte: 
Task 4 COLLABORATIVE STUDY 
e-mail: 
fax: 
telephone: 
I MADURAMICIN 
Sample code 
292246 
292262 
292295 
292305 
292322 
292325 
292330 
292342 
292343 
292361 
Unit 
Result 
(mg/kg) 
2,41 
2,84 
0 
5,01 
10,90 
0 
5,79 
10,63 
5,25 
5,57 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
643,60 
Result 2 
(mg/kg) 
710,50 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Annex 4 - Questionnaire 
3 
3?fP$$8 
5
' "J^ffî 
Date(s) of analysis: ! . § / . l ^ . . . . . ^ n W î O A y . . . . . ^ B 9 . . l . 
Dilution fartnr nf the samples: 
• Feed samples (specify for which feed samples): 
• Premixture: 
Chromatnpraphir. conditions 
• Column: 
• 0 As described in the method 
• EOther: 
• Mobile phase: 
• # As described in the method 
• D Other: 
» FloviH-ate:... Of& m|/min 
I UIC MICUIUU 
.^foeiàLSad» .Q^.%.....0$...3^<n A.fe.250Tv^ 
Injection volume: J20S..pl ,7P\ 
• Retention time of maduramicin: .ft?'... min 
Chromatograms: Please injuria representative chromatograms of; 
• Blind positive feed samples 
• Blind blank feed sample 
• Premixture 
Please indicate the maduramicin peak with an arrow 
Recovery rpsnltsr g 
• Percentage recovery: *£?!. % 
• Single / duplicate determinations: D single # duplicate 
• If duplicate, please give both percentages: %5. % and J!QQ% 
• Spiking level: ...5 mgAg 
® 
Maduramicin Report 
Project Name: Maduramicin 
SAMPLE INFORMATION 
Sample Name: Sample 292325 
Sample Type: Unknown 
Vial: 38 
Injection #: 1 
Injection Volume: 200,00 ul 
Run Time: 30,0 Minutes 
Date Acquired: 16-01-200119:47:26 
Acq. Method Set Maduramicin CANFAS 
Date Processed: 16-01-200120:22:46 
Processing Method: MAD 16 01 2001 
Proc. Chnl. Descr.: PDA 520,0 nm 
Auto-Scaled Chromatogram 
0,01O 
- i—i—|—i—i—!—|—i—I—i—|—i—i—I—j—i—i—i—i—I—I—I—I—I—I—i—i—I—I—I—i—i—i—i—I—i—i—i—j—r— ;—i—|—i—|—,—,-> 
2,00 4,00 6,00 8,00 10,00 12,00 14.00 16.00 18,00 20,00 22.00 24,00 
Mnutes 
1 
Name 
MAO 
Peak F 
FT 
20,432 
Area 
Sesults 
Height Amount Unto 
"Blfnd Mahk &&£ ,se?rr>pk 
(à 
Maduramicin Report 
Project Name: Maduramicin 
SAMPLE INFORMATION 
Sample Name: Sample 292262 
Sample Type: Unknown 
Vial: 40 
Injection #: 1 
Injection Volume: 200,00 ul 
Run Time: 30,0 Minutes 
Dote Acquired: 16-01-200119:13:37 
Acq. Method Set Maduramicin CANFAS 
Date Processed: 16-01-2001 20:22:47 
Processing Method: MAD 16 01 2001 
Proc. Chnl. Desa.: PDA 520,0 nm 
Auto-Scaled Chromatogram 
0,01a 
0,008 
0.006H 
3 
< 
0.004H 
0.002H 
i,ooo-Hf— 
• ' ' ' I ' _ i -'-- .~ ~ . tnnn *A nn i c nn mnn onnn v> nn m « — 2,00 4,00 6,00 8,00 10,00 12,00 14,00 16.00 18,00 20,00 22,00 24,00 26,00 28,00 
Mnutes 
1 
Name 
MAD 
PeakR 
RT 
20,319 
Area 
51066 
»suits 
Height 
729 
Amount 
0,568 
Units 
ug/mt 
i 
2,04 mj lUfr 
"Blind pÄt-fwe {esJ s»noP(c 
Maduramicin Report 
Project Name: Maduramicin 
SAMPLE I N F O R M A T I O N 
Sample Name: PM 12II 
Sample Type: Unknown 
Vial: 36 
Injection #: 1 
Injection Volume- 200,00 ul 
Run Time: 30,0 Minutes 
Date Acquired: 16-01-200115:29:50 
Acq. Method Set: Maduramicin CANFAS 
Date Processed: 16-01-200120:22:46 
Processing Method: MA016 012001 
Proc. Chnl. Desa.: PDA 520,0 nm 
Auto-Scaled Chromatogram 
0,012 
0,010-
0,008-
=> 0,006-
< 
0,004-
0,002-
o,ooo-~-\A 
i—|—i—i—i—|—i—i—i—|—i—i—i—i—i—i—i—|—i—i—r—|—i—i—i—|—i—i—i—|—i—i—i—|—i—i—, | i—i—i—1—, Y i—r 
2,00 4,00 6.00 8,00 10,00 12,00 14,00 16,00 18,00 20,00 22,00 24,00 
Mnutes 
Peak Results 
1 
Name 
MAD 
RT 
20,043 
Area 
1021690 
Height 
9656 
Amount 
12,872 
Units 
ug/irt 
I 
éAiGO mj/C^ 
TWrtuV-fuofi. 
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Annex 2 
CANFAS 
: Development and Validation of HPLC-methods for the official control of 
ICoccidiostats and Antibiotics used as Feed Additives (SMT4-CT98-2216) 
Subtitle: 
Lab-name: 
Contact person: 
Date of analysis: 
Analyte: 
Task 4 COLLABORATIVE STUDY 
e-mail: 
fax: 
telephone: 
MADURAMICIN 
Sample code 
302274 
302290 
302296 
302315 
302316 
302318 
302324 
302328 
302329 
302356 
Unit 
Result 
(mg/kg) 
3,0 
8,9 
6,6 
<1 
2,4 
10,4 
3,1 
5
-
3 
1,7 
<1 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
491 
Result 2 
(mg/kg) 
511 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 • MADURAMICIN 
Annex 4 - Questionnaire 
Datc(s) of analyse 6is: <J.4ifA$./jß.G. 
DjlMfjon factor f?f the samples: 
• FBBW samples (specify for which feed samples ) : . . •^ £ ^- - \o . . .S> .0 . .m l . 
. Premixture: * /q. . . . :hs, . . .5£?.Ytt i . 
ChromatoeranWr conditions: 
• Column: 
• D As described in the method 
• D Other: ...HviOa.m»Ävf. C^iS jfSü...at..A.»£.X*XTC . S ^ m . 
• Mobile phase: 
• -T£As described In the method 
• o Other: 
• Fk»H«te:...-Û*4--nWnh 
• Injection volume: .SO... . j i 
• Retention time of madurarnicln:«i^ k mto 
«.rnmatopt-amr p ' » a s g fnfïlllftf r r M M M * w chronrntomranK of; 
• Blind positive feed samples 
• Blind blank feed sample 
• Premature 
Please mdcete the maduromicin peak with an arrow 
Recovery results; 
• Percentage recovery: M > % 
• Single / duplicate determinations: j i n g l e D duplicate 
. If duplicate, please give both percentages: % and % 
• Spiking level: 5 . . . mg/kg 
X 
-0.20 
0.00 
Mlnut«3 
i'bS) 
30.00 
SampleName: 302328 Vial: 10 In]: 1 Ch: SATIN Type: Unknown 
' t^os^V .v t . §**£ »«.ws^A-c- C Sy%> VÇ , Y r») 
0 .60-
0.40 
% 
0.20-
0.00-
0 . 0 0 5 . 0 0 
Minutes 
SampteName: 3023S6 Vial: 12 inj: 1 Ch: SATIN Type: Unknown 
3.00 
2.50 
2.00 
% 
1.50 
1.00 
O.SO 
. 0 . 0 0 . 5 . 0 0 
Minute« 
SampleName: PREMIX 1 Vial: 16 Inj: 1 Ch: SATIN Typ«- Unknown 
i 1—r 
30.00 
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Annex 2 
CAN FAS 
Development and Validation of HPLC-methods for the official control of 
Çoccidiostats and Antibiotics used as Feed Additives (SMT4-CT98-2216) 
Subtitle: 
Lab-name: 
Contact person: 
Date of analysis: 
Analyte: 
Task 4 COLLABORATIVE STUDY 
e-mail: 
fax: 
telephone: 
MADURAMICIN 
Sample code 
312233 
312247 
312264 
312307 
312331 
312334 
312357 
312359 
312362 
312367 
Unit 
Result 
(mg/kg) 
4,9 
0 
0 
9,0 
2,3 
4,4 
4,9 
3,0 
4,9 
9,1 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
469 
Result 2 
(mg/kg) 
444 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Annex 4 - Questionnaire 
Date(s) of analysis: ...LT:.Ü..,..ZD..0.Q....±....^-.AZ^.1.Q^Q.. 
Dilution factor nf thP samnles: 
• Feed samples (specify for which feed samples):... . 
. UnlilutU 
• Premixture: ?T...?...).£ 
Chromatographic conditions; 
• Column: 
• £As described in the method 
• D Other: 
• Mobile phase: 
• & As described in the method 
• ü Other: 
• Flowrate: & & . . . . m|/min 
• Injection volume: ...l#f?...ul 
• Retention time of maduramicin: Z at ?.. min 
Chromatof rams: Please mtAuda representative chromatPErams Oft 
• Blind positive feed samples 
• Blind blank feed sample 
• Premixture 
Please indicate the maduramicin peak with an arrow 
Recovery results; - ^ 7 - - . Day % 
• Percentage recovery: .^p% j ^ , ^ . & / 
• Single /duplicate determinations: D single gt duplicate 
• If duplicate, please give both p e r c e n t a g e s : ^ % and \Qv,b % \\° )5~ ^ \o(, l °/ 
• Spiking level: b. . . mgAg b
^/U 1> 
Software Version 
Sample Name 
Instrument Name 
Rack/Vial 
Sample Amount 
Cycle 
6.1.1.0.0:K20 
24860 . 
HPLC-1 
0/0 
1,000000 
13 
W- 3\Z33i 
Date 
Data Acquisition Time 
Channel 
Operator 
Dilution Factor 
(jj) 
Page 1 of 1 
8-12-2000 9:20:49 
7-12-2000 17:04:44 
A 
1,000000 
Result File : \\l ' 
Sequence File : \\ 
I I I I I M | M I 
§ 
s I I I I M i l 
20 30 
TJT-T 
35 Time Iminl 
maduramvcin (NH4+) 
39842,91 1701,93 100,00 
Missing Component Report 
Component Expected Retention (Calibration File) 
All components were found 
100,00 
"H 
bak Time 
'# [min] 
1 20,74 
2 23,17 
3 28,45 
4 32,05 
5 33,03 
6 36,94 
7 38,21 
8 39,62 
Component 
Name 
maduramycin 
Area 
[uVs] 
2163,00 
20915,41 
2067,00 
1478,00 
4980,00 
1907,50 
2413,00 
3919,00 
Height 
[uV] 
188,18 
436,55 
139,01 
234,63 
97,19 
221,36 
176,27 
208,73 
Area 
[%] 
5,43 
52,49 
5,19 
3,71 
12,50 
4,79 
6,06 
9,84 
Norm. Area 
[%] 
5,43 
52,49 
5,19 
3,71 
12,50 
4,79 
6,06 
9,84 
BL 
BB 
MM 
BB 
BB 
BB 
BB 
BB 
BB 
Area/Height 
[s] 
11,4944 
47,9102 
14,8694 
6,2992 
51,2401 
8,6171 
13,6896 
18,7751 
yiiM E 1,1" 1 / 
ï^ln&hxA) Ol 
Page 1 öTl 
Software Version 
Sample Name 
Instrument Name 
Rack/Vial 
Sample Amount 
Cycle 
Result File : \\ 
Sequence File : \Y 
6.1.1.0.0.K20 
24863-b : 
HPLC-1 
0/0 
1,000000 
17 
Date 
Data Acquisition Time 
Channel 
Operator 
Dilution Factor 
8-12-2000 9:27:17 
7-12-2000 19:51:21 
A 
1,000000 
I I 
«eak Time 
™# [min] 
1 20,41 
2 23,60 
3 26,46 
4 30,47 
5 31.09 
6 32,22 
7 36,11 
8 37,92 
9 38,13 
10 38,49 
11 39,77 
I I | I I I 
5 
Component 
Name 
maduramycin 
I | ! I I 
10 
I j I I 
15 
1
 ' 1 
20 
Time (min 
maduramycin 
Area 
[uVs] 
3649,00 
45399,16 
383,00 
7126,63 
3012,87 
2429,00 
1702,50 
2979,30 
1660,20 
1240,00 
2110,00 
Height 
[uVJ 
160,87 
602,66 
108,15 
201,58 
209,37 
178,60 
156,83 
172,37 
167,09 
176,03 
145,53 
Area 
[%] 
5,09 
63,33 
0,53 
9,94 
4,20 
3,39 
2,37 
4,16 
2,32 
1,73 
2,94 
I > I | I I ! 
25 
1 
(NH4+) 
Norm. Area BL 
[%] 
5,09 BB 
63,33 MM 
0,53 BB 
9,94 BV 
4,20 VB 
3,39 BB 
2,37 BB 
4,16 BV 
2,32 VB 
1,73 BB 
2,94 BB 
1
 i ' i i i 1 i i i n 
M 35 ' 
— 
Area/Height 
[s] 
22,6829 
75,3313 
3.5412 
35,3539 
14,3901 
13,6004 
10,8559 
17,2845 
9,9358 
7,0443 
14,4991 
71691,66 2279,08 100,00 
Missing Component Report 
Component Expected Retention (Calibration File) 
All components were found 
100,00 
P 
Software Version 
Sample Name 
Instrument Name 
Rack/Vial 
Sample Amount 
Cycle 
Result File : \\ ( 
Sequence File : \ 
6.1.1.0.0:K?n 
24858 .. 
HPLC-1 
0/0 
1.000000 
11 
hr. ZiioJ-i/ 
Date 
Data Acquisition Time 
Channel 
Operator 
Dilution Factor 
Page 
12/7/00 4:21:33 PM 
12/7/00 3:41:25 PM 
A 
1.UOO000 
O a 
s 
CO t -
1 1 
Time [min] 
maduramycin. (NH4+) 
Peak Time 
# [min] 
- 23.00 
1 26.25 
2 28.15 
3 30.40 
4 30.65 
5 34.22 
6 36.31 
7 37.14 
8 38.21 
9 39.05 
Component 
Name 
maduramycir. 
Area 
[uVs] 
0.00 
1751.00 
1725.50 
1338.50 
4127.00 
16368.00 
1295.63 
6454.80 
1971.00 
965.00 
Height 
[uV] 
0.00 
104.94 
111.39 
145.41 
152.17 
270.34 
122.70 
98.28 
167.86 
164.66 
Area 
[%J 
0.00 
4.86 
4.79 
3.72 
11.47 
45.47 
3.60 
17.93 
5.48 
2.68 
Norm. Area 
[%] 
0.00 
4.86 
4.79 
3.72 
11.47 
45.47 
3.60 
17.93 
5.48 
2.68 
BL Area/Height 
BB 
BB 
BB 
BB 
BB 
BV 
VB 
BB 
BB 
[si 
16.6863 
15.4901 
9.2052 
27.1208 
60.5451 
10.5595 
65.6773 
11.7419 
5.8605 
35996.43 1337.75 100.00 
Missing Component Report 
Component Expected Retention (Calibration File) 
maduramycir 23.000 
100.00 
W W CO UC -^
M- 31236 O ! / 
Page Tof 1 
Software Version 
Sample Name 
Instrument Name 
Rack/Vial 
Sample Amount 
Cycle 
6.1.1.0.0:K20 
24861 
HPLC-1 
0/0 
1,000000 
14 
Date 
Data Acquisition Time 
Channel 
Operator 
Dilution Factor 
8-12-2000 11:04:04 
7-12-2000 17:46:23 
A 
'1,000000 
Result File : \) ... x. 
Sequence File : '.,, 
ui 
\rr ?eq 
I I 
fpak Time 
w# [min] 
1 20,40 
2 20,75 
3 20,96 
4 23,25 
5 25,96 
6 26,49 
7 27,59 
8 31,58 
9 32,43 
10 33,33 
11 39 ,79 
I I | I l l 
s 
Component 
Name 
maduramycin 
I | I I I 
10 
I I I l 
15 
I I j I 
20 
Time fmin 
maduramycin 
Area 
ftiV-s] 
1446,57 
1028,11 
1204,00 
45697.05 
1511,00 
2652,00 
4840,50 
4084,00 
868,50 
1246,00 
3680,00 
Height 
[MV] 
148,58 
158,51 
147,81 
774,05 
155,96 
181,97 
50,46 
146,25 
106,17 
150,36 
198,86 
Area 
l%] 
2,12 
1,51 
1,76 
66,95 
2,21 
3,89 
7,09 
5,98 
1,27 
1,83 
5,39 
3 
§ 
5 
I I I I I 
25 
(NH4+) 
Norm. Area 
[%] 
2,12 
1,51 
1,76 
66,95 
2,21 
3,89 
7,09 
5,98 
1,27 
1,83 
5,39 
I I 
BL 
BV 
VB 
BB 
MM 
BB 
BB 
BB 
BB 
BB 
BB 
BB 
| M I I j I | M [ 
30 35 
Area/Height 
[s] 
9,7363 
6,4859 
8,1454 
59,0359 
9,6881 
14,5741 
95,9245 
27,9257 
8,1805 
8,2869 
18,5059 
68257,73 2218,98 100,00 100,00 
Missing Component Report 
Component Expected Retention (Calibration File) 
All components were found l\iyU I M , ^ Jjfa 
: \ 
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Annex 2 
CAN FAS 
Development and Validation of HPLC-methods for the official control of 
Çoccidiostats and Antibiotics used as Feed Additives (SMT4-CT98-2216) 
Subtitle: 
Lab-name: 
Contact person: 
Date of analysis: 
Analyte: 
Task 4 COLLABORATIVE STUDY 
e-mail: 
fax: 
telephone: 
I MADURAMICIN 
Sample code 
352256 
352265 
352284 
352310 
352314 
352320 
352332 
352348 
352358 
352366 
Unit 
Result 
(mg/kg) 
4,5 
<2 
4,0 
2,2 
1,9 
3,9 
8,7 
3,8 
7,3 
<2 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
385 
Result 2 
(mg/kg) 
378 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Annex 4 - Questionnaire 
Date(s) of analysis: J.Ô./Û./../Û./.... 
Dilution factor of the samples: 
• Feed samples (specify for which feed samples):.. <5.vR. 
• Premixture: .5.QQ.. 
Chromatographic renditions: 
• Column: 
• a As described in the method 
• pother: 2ldtl&Xf}}to.JQQ...£îjfl..Ù.fî&y 
• Mobile phase: 
• g As described in the method 
• D Other: 
• Flow-rate:.. .0, M ml/min 
• Injection volume: .SQ.....ul 
• Retention time of madurarnicin: 7Z+ S. min 
Chromatagrams: Please Include representative chromatngrafm pf; 
• Blind positive feed samples 
• Blind blank feed sample 
• Premixture 
Please indicate the madurarnicin peak with an arrow 
Recovery results: 
• Percentage recovery: j } P*3. % 
• Single / duplicate determinations: 0 single M duplicate 
• If duplicate, please give both percentages: 3.],?. % andj}S*J. % 
• Spiking level: . . IP mg/kg 
Maduramycin 
Monster: 7 49-0514 .=• 3S2lV5 
Gebruiker: asc 
Runtijdstip: 01-09-2001 13:43:47 
Inweeg: 9.9859 
Verdunning : 50 
Methode: \\Fs_i \VOLl\DATA\EliteJ^dmin\Projects\Testlab\Method\I 
File: \\Fs_ \VOLl\DATA\Elite_Admin\Projects\Testlab\Data 
Sequence: \\Fs_ ' \VOLl\DATA\EIiteJkdmin\Projects\Testlab\Sequence, 
0.004 
o.ooo-
0.004 
-0.002 
•0.000 
Peak: Maduramycin - ESTD - UV-Detector 
50000 100000 
Area 
UV-Detector 
Results 
Name Retention 
Time 
Area Height ESTD Units 
concentration 
Maduramycin 0.000 BDL mg/kg 
Maduramycin 
Monster: 3 49-0512 = 3 5 2 2 5 te 
Gebruiker: 
Runtijdstip: 01-09-2001 13:43:38 
Inweeg: 10.1907 
Verdunning : 50 
Methode: 
File: 
Sequence: 
\\Fs 
\\Fs. 
\\Fs. 
0.004 
)\VOLl\DATA\Elite_Admin\Projects\TestIab\Method\Maduramycin 
. J W O L 1 \DATA\Elite_Admin\Projects\Testlab\Data\Maduramycin. 
WOL 1 \DATA\Elite_Admin\Projects\TestIab\Sequence\Madurarnycip 
0.004 
0.002 
h 0.000 
0 5 10 
Peak: Maduramycin - ESTD - UV-Detector 
15 
Minutai 
I 
50000 100000 
Area 
UV-Detector 
Results 
Name Retention 
Time 
Area Height ESTD Units 
concentration 
Maduramycin 22.300 49658 1036 4.549 mg/kg 
Maduramycin 
Monster: 23 49-0522 pr. .=- Û(L£m' X 
Gebruiker: asc 
Runtijdstip: 01-09-2001 13:44:06 
Inweeg: 1.0425 
Verdunning : 500 
f35\ 
Methode: 
File: 
Sequence: 
\\Fs 
\\Fs . 
\VFs_ 
.VOLl\DATA\Elite_Admin\Projects\Testlab\MethodV.: 
\VOLl\DATA\Elite_Admin\Projects\Testlab\Data\I 
WOL 1 \DATA\Elite_Admin\ProjectsY^estlab\Seque^ce^ 
0.004 0.004 
0.002 
Peak: Maduramycir . - ESTD - UV-Delector 
50000 100000 
Area 
UV-Detector 
Results 
Name Retention 
Time 
Area Height ESTD Units 
concentration 
Maduramycin 22.300 45712 1160 384.558 mg/kg 
APPENDIX 5 
Table with results, questionnaire (page 1) and chromatograms 
of partner 36 
Annex 2 
CAN FAS 
Development and Validation of HPLC-methods for the official control of 
Çoccidiostats and Antibiotics used as Feed Additives (SMT4-CT98-2216) 
Subtitle: 
Lab-name: 
Contact person: 
Date of analysis: 
Analyte: 
Task 4 COLLABORATIVE STUDY 
e-mail: 
fax: 
telephone: 
MADURAMICIN 
Sample code 
362258 
362270 
362288 
362291 
362297 
362313 
362317 
362340 
362351 
362363 
Unit 
Result 
(mg/kg) 
2,8 
8,6 
4
-
7 
5,0 
0 
5,1 
3,8 
0 
2,5 
8,4 
Unit 
Sample 
Premixture 
Result 1 
(mg/kg) 
444 
Result 2 
(mg/kg) 
479 
3t 
CANFAS COLLABORATIVE STUDIES OCTOBER 2000 - MADURAMICIN 
Annex 4 • Questionnaire 
Date(s) of analysis: 20:12.2000 
Dilution factor nf the samples: 
• Feed samples (specify for which feed samples): /.....?..}!)..?P„M. 
. FVemixture:...I:P..9..Än.MM../..5.!!U.dÜUt^ i.to » M 
Chromatographic conditions: 
• Column: 
• o As described in the method 
. » other: ..dypersiL.0DSv5.McxD0],..25Q.x.A.jnn 
• Mobile phase: 
• D As described in the method 
. » other: .lM.M..phosphate.buf.fen..pH..Arm m l 
. Row-rate: ...Q,M. m|/min vmi th methanol 
• Injection volume: .2W pi 
• Retention time of maduramicin: ..16... min 
Chromatograms: Please include representative chromatograms of: 
• Blind positive feed samples 
• Blind blank feed sample 
• Premixture 
Please inécate the maduramicin peak with an arrow 
Recovery results: 
• Percentage recovery: % 
• Single / duplicate determinations: D single D duplicate 
• If duplicate, please give both percentages: % and % 
• Spiking level: mgAg 
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Appendix 6 
Results of special requests: 
Results of Hoffmann-La Roche applying post-column derivatisation with DMAB 
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Appendix 6 
Results of special requests: 
Results of LUFA-Augustenberg applying post-column derivatisation with DMAB 
7. FEB. 2001 14:44 LUFA AUGUSTKJime iu. o o o ». J 
CANFAS COLLABORATIVE STUDIES OCTOBER 2 0 0 0 - MADURAMICIN 
Annex 4 • Questionnaire 
Uff A fotfi^Le 
Contact person: 
Laboratory: ,.
 Y..,„. ... 
Datefs, of a n a * * : ££L:3*J±***± 
Kltrfjon factor of the samples; 
• Feed samples (specify for which feed samples): 
/ók JF.Ar*T.e.tz rif.. ÎT.tÀt..d!. 
. Premixture: .//Je. #œ/z.*>.7*,..tr?.. iT»h&t..4. HfJ'g. 
Chromatographic conditions: 
• Column: 
• O As described in the method 
.}*$*m ...tyjx„cf.tâ„...tâ£.t...J^ ££*„£...&.&., 
• Mobile phase: 
• ^ ^ A S described in the method 
• O Other: 
• Flow-rate: .$/.Z.. mVmm 
• Injection volume: *&££..$ 
• Retention time of maduramicin^r.T., mil rrnn 
CtirofnatnyraniK Ptease Indutte r«nrpsem«th/» chrwtnatwfmm* «f; 
• Blind positive feed samples 
• Blind blank feed sample 
• Premixture 
Please indicate the maduramkm peakwith an arrow 
Recovery results: J0J fC 
• Percentage recovery: X y 
• Single / duplicate déterminations: D single ^duplicate 
• If duplicate, please give both percentages: % and % 
• Spiking level: ...£?.... mg/kg "t^W / îi,iC 
~ ?-
• 7. FEB. 2001 14:44 
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